{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T15:42:17Z","timestamp":1793374937688,"version":"4.5.0"},"reference-count":327,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Dis Primers"],"DOI":"10.1038\/s41572-026-00714-w","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T07:01:57Z","timestamp":1782370917000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Primary aldosteronism"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0314-9252","authenticated-orcid":false,"given":"Anand","family":"Vaidya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory A.","family":"Kline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Mulatero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adina F.","family":"Turcu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2388-6444","authenticated-orcid":false,"given":"Tracy Ann","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7935-0991","authenticated-orcid":false,"given":"Vin-Cent","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4620-4976","authenticated-orcid":false,"given":"Jun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5449-9191","authenticated-orcid":false,"given":"Maria-Christina","family":"Zennaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4137-3025","authenticated-orcid":false,"given":"Andr\u00e9","family":"Lacroix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"key":"714_CR1","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","volume":"45","author":"JW McEvoy","year":"2024","unstructured":"McEvoy, J. W. et al. 2024 ESC guidelines for the management of elevated blood pressure and hypertension. Eur. Heart J. 45, 3912\u20134018 (2024).","journal-title":"Eur. Heart J."},{"key":"714_CR2","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(25)01853-7","volume":"406","author":"GBD 2023 Chronic Kidney Disease Collaborators","year":"2025","unstructured":"GBD 2023 Chronic Kidney Disease Collaborators. Global, regional, and national burden of chronic kidney disease in adults, 1990\u20132023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023. Lancet 406, 2461\u20132482 (2025).","journal-title":"Lancet"},{"key":"714_CR3","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1210\/er.2018-00139","volume":"39","author":"A Vaidya","year":"2018","unstructured":"Vaidya, A., Mulatero, P., Baudrand, R. & Adler, G. K. The expanding spectrum of primary aldosteronism: implications for diagnosis, pathogenesis, and treatment. Endocr. Rev. 39, 1057\u20131088 (2018). Initial review that brought attention to the much more diverse spectrum and frequent prevalence of PA than previously believed.","journal-title":"Endocr. Rev."},{"key":"714_CR4","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/s41574-022-00730-2","volume":"18","author":"AF Turcu","year":"2022","unstructured":"Turcu, A. F., Yang, J. & Vaidya, A. Primary aldosteronism \u2014 a multidimensional syndrome. Nat. Rev. Endocrinol. 18, 665\u2013682 (2022).","journal-title":"Nat. Rev. Endocrinol."},{"key":"714_CR5","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/j.jacc.2017.01.052","volume":"69","author":"S Monticone","year":"2017","unstructured":"Monticone, S. et al. Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. J. Am. Coll. Cardiol. 69, 1811\u20131820 (2017).","journal-title":"J. Am. Coll. Cardiol."},{"key":"714_CR6","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1210\/clinem\/dgaf284","volume":"110","author":"GK Adler","year":"2025","unstructured":"Adler, G. K. et al. Primary aldosteronism: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 110, 2453\u20132495 (2025). The 2025 clinical practice guideline by the Endocrine Society, which recommends screening for PA in all patients with hypertension using simplified and liberalized approaches to increase diagnosis and specific treatment of PA.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"714_CR7","doi-asserted-by":"publisher","first-page":"101526","DOI":"10.1016\/j.jacbts.2026.101526","volume":"11","author":"S Parisien-La Salle","year":"2026","unstructured":"Parisien-La Salle, S. et al. Unmasking hormonal mechanisms of hypertension in obesity. JACC Basic Transl. Sci. 11, 101526 (2026).","journal-title":"JACC Basic Transl. Sci."},{"key":"714_CR8","doi-asserted-by":"publisher","first-page":"10","DOI":"10.7326\/M20-0065","volume":"173","author":"JM Brown","year":"2020","unstructured":"Brown, J. M. et al. The unrecognized prevalence of primary aldosteronism: a cross-sectional study. Ann. Intern. Med. 173, 10\u201320 (2020). Highly cited multicentre study showing a high-to-very high prevalence of PA beginning with pre-hypertensive individuals and increasing in prevalence with progressively greater degrees of hypertension.","journal-title":"Ann. Intern. Med."},{"key":"714_CR9","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1056\/NEJMoa2507109","volume":"393","author":"JM Flack","year":"2025","unstructured":"Flack, J. M. et al. Efficacy and safety of baxdrostat in uncontrolled and resistant hypertension. N. Engl. J. Med. 393, 1363\u20131374 (2025).","journal-title":"N. Engl. J. Med."},{"key":"714_CR10","doi-asserted-by":"publisher","first-page":"289","DOI":"10.7326\/M20-4873","volume":"174","author":"JB Cohen","year":"2021","unstructured":"Cohen, J. B. et al. Testing for primary aldosteronism and mineralocorticoid receptor antagonist use among U.S. veterans: a retrospective cohort study. Ann. Intern. Med. 174, 289\u2013297 (2021). Initial study, along with refs. 11\u201313, that showed very low screening rates in patients with hypertension who met previous guideline indications for screening; these led to current recommendations to screen all patients with hypertension for PA.","journal-title":"Ann. Intern. Med."},{"key":"714_CR11","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1001\/jamasurg.2021.0254","volume":"156","author":"YY Liu","year":"2021","unstructured":"Liu, Y. Y. et al. Outcomes of a specialized clinic on rates of investigation and treatment of primary aldosteronism. JAMA Surg. 156, 541\u2013549 (2021).","journal-title":"JAMA Surg."},{"key":"714_CR12","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1161\/HYPERTENSIONAHA.121.18118","volume":"79","author":"GL Hundemer","year":"2022","unstructured":"Hundemer, G. L. et al. Screening rates for primary aldosteronism among individuals with hypertension plus hypokalemia: a population-based retrospective cohort study. Hypertension 79, 178\u2013186 (2022).","journal-title":"Hypertension"},{"key":"714_CR13","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.025952","volume":"11","author":"AF Turcu","year":"2022","unstructured":"Turcu, A. F. et al. Primary aldosteronism screening rates differ with sex, race, and comorbidities. J. Am. Heart Assoc. 11, e025952 (2022).","journal-title":"J. Am. Heart Assoc."},{"key":"714_CR14","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S2213-8587(17)30319-4","volume":"6","author":"S Monticone","year":"2018","unstructured":"Monticone, S. et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 6, 41\u201350 (2018). Important meta-analysis that demonstrated the increased cardiovascular morbidity of PA compared with essential hypertension.","journal-title":"Lancet Diabetes Endocrinol."},{"key":"714_CR15","doi-asserted-by":"publisher","first-page":"630","DOI":"10.7326\/M17-0882","volume":"167","author":"JM Brown","year":"2017","unstructured":"Brown, J. M. et al. The spectrum of subclinical primary aldosteronism and incident hypertension: a cohort study. Ann. Intern. Med. 167, 630\u2013641 (2017).","journal-title":"Ann. Intern. Med."},{"key":"714_CR16","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1161\/HYPERTENSIONAHA.120.15006","volume":"76","author":"K Inoue","year":"2020","unstructured":"Inoue, K. et al. Serum aldosterone concentration, blood pressure, and coronary artery calcium: the multi-ethnic study of atherosclerosis. Hypertension 76, 113\u2013120 (2020).","journal-title":"Hypertension"},{"key":"714_CR17","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1161\/CIRCULATIONAHA.123.066389","volume":"149","author":"GL Hundemer","year":"2024","unstructured":"Hundemer, G. L. et al. Subclinical primary aldosteronism and cardiovascular health: a population-based cohort study. Circulation 149, 124\u2013134 (2024). This study shows that the spectrum of aldosterone dysregulation is associated with cardiovascular risk and identifies that ARR >2.5 is associated with increased cardiovascular risk.","journal-title":"Circulation"},{"key":"714_CR18","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1161\/CIRCULATIONAHA.124.070039","volume":"150","author":"RA Ananda","year":"2024","unstructured":"Ananda, R. A. et al. Relationship between renin, aldosterone, aldosterone-to-renin ratio and arterial stiffness and left ventricular mass index in young adults. Circulation 150, 2019\u20132030 (2024).","journal-title":"Circulation"},{"key":"714_CR19","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1161\/CIRCULATIONAHA.124.073507","volume":"152","author":"R Goupil","year":"2025","unstructured":"Goupil, R. et al. Subclinical primary aldosteronism and major adverse cardiovascular events: a longitudinal population-based cohort study. Circulation 152, 913\u2013923 (2025).","journal-title":"Circulation"},{"key":"714_CR20","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1093\/ajh\/hpaf183","volume":"39","author":"RR Townsend","year":"2026","unstructured":"Townsend, R. R. et al. Risk of hypertension and chronic kidney disease following aldosterone dysregulation. Am. J. Hypertens. 39, 161\u2013170 (2026).","journal-title":"Am. J. Hypertens."},{"key":"714_CR21","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1507\/endocrj.EJ21-0508","volume":"69","author":"M Naruse","year":"2022","unstructured":"Naruse, M. et al. Japan Endocrine Society clinical practice guideline for the diagnosis and management of primary aldosteronism 2021. Endocr. J. 69, 327\u2013359 (2022).","journal-title":"Endocr. J."},{"key":"714_CR22","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1016\/j.jacc.2025.05.007","volume":"86","author":"DW Jones","year":"2025","unstructured":"Jones, D. W. et al. 2025 AHA\/ACC\/AANP\/AAPA\/ABC\/ACCP\/ACPM\/AGS\/AMA\/ASPC\/NMA\/PCNA\/SGIM guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines. J. Am. Coll. Cardiol. 86, 1567\u20131678 (2025).","journal-title":"J. Am. Coll. Cardiol."},{"key":"714_CR23","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1001\/jama.1965.03090030022005","volume":"193","author":"JW Conn","year":"1965","unstructured":"Conn, J. W., Cohen, E. L., Rovner, D. R. & Nesbit, R. M. Normokalemic primary aldosteronism. a detectable cause of curable \u201cessential\u201d hypertension. JAMA 193, 200\u2013206 (1965).","journal-title":"JAMA"},{"key":"714_CR24","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1001\/archinte.1975.00330020151022","volume":"135","author":"CE Grim","year":"1975","unstructured":"Grim, C. E. Low renin \u201cessential\u201d hypertension: a variant of classic primary aldosteronism? Arch. Intern. Med. 135, 347\u2013350 (1975).","journal-title":"Arch. Intern. Med."},{"key":"714_CR25","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1161\/HYPERTENSIONAHA.116.08952","volume":"69","author":"R Baudrand","year":"2017","unstructured":"Baudrand, R. et al. Continuum of renin-independent aldosteronism in normotension. Hypertension 69, 950\u2013956 (2017).","journal-title":"Hypertension"},{"key":"714_CR26","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1097\/00004872-200311000-00025","volume":"21","author":"M Stowasser","year":"2003","unstructured":"Stowasser, M. et al. High rate of detection of primary aldosteronism, including surgically treatable forms, after \u2018non-selective\u2019 screening of hypertensive patients. J. Hypertens. 21, 2149\u20132157 (2003).","journal-title":"J. Hypertens."},{"key":"714_CR27","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1210\/jc.2003-031337","volume":"89","author":"P Mulatero","year":"2004","unstructured":"Mulatero, P. et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J. Clin. Endocrinol. Metab. 89, 1045\u20131050 (2004).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"714_CR28","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1016\/j.jacc.2006.07.059","volume":"48","author":"GP Rossi","year":"2006","unstructured":"Rossi, G. P. et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J. Am. Coll. Cardiol. 48, 2293\u20132300 (2006). An early systematic study using ARR and captopril test in a large Italian cohort of patients with hypertension, which found that 4.8% had an APA and 6.4% had bilateral PA.","journal-title":"J. Am. Coll. Cardiol."},{"key":"714_CR29","doi-asserted-by":"publisher","first-page":"2826","DOI":"10.1210\/jc.2016-1472","volume":"101","author":"SC Kayser","year":"2016","unstructured":"Kayser, S. C. et al. Study heterogeneity and estimation of prevalence of primary aldosteronism: a systematic review and meta-regression analysis. J. Clin. Endocrinol. Metab. 101, 2826\u20132835 (2016).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"714_CR30","doi-asserted-by":"publisher","first-page":"102791","DOI":"10.1016\/j.cpcardiol.2024.102791","volume":"49","author":"M Huang","year":"2024","unstructured":"Huang, M. et al. Global and regional prevalence and cardiovascular risk of primary aldosteronism: a systematic review and meta-analysis. Curr. Probl. Cardiol. 49, 102791 (2024).","journal-title":"Curr. Probl. Cardiol."},{"key":"714_CR31","doi-asserted-by":"publisher","first-page":"R1","DOI":"10.1530\/EJE-21-0031","volume":"185","author":"K Nanba","year":"2021","unstructured":"Nanba, K. & Rainey, W. E. Genetics in endocrinology: impact of race and sex on genetic causes of aldosterone-producing adenomas. Eur. J. Endocrinol. 185, R1\u2013R11 (2021). Informative review on variation in somatic mutations of PA driver genes according to ethnic race and age in various populations.","journal-title":"Eur. J. Endocrinol."},{"key":"714_CR32","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1161\/HYPERTENSIONAHA.118.12070","volume":"73","author":"K Nanba","year":"2019","unstructured":"Nanba, K. et al. Genetic characteristics of aldosterone-producing adenomas in blacks. Hypertension 73, 885\u2013892 (2019).","journal-title":"Hypertension"},{"key":"714_CR33","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1210\/js.2018-00097","volume":"2","author":"W Warachit","year":"2018","unstructured":"Warachit, W., Atikankul, T., Houngngam, N. & Sunthornyothin, S. Prevalence of somatic KCNJ5 mutations in Thai patients with aldosterone-producing adrenal adenomas. J. Endocr. Soc. 2, 1137\u20131146 (2018).","journal-title":"J. Endocr. Soc."},{"key":"714_CR34","doi-asserted-by":"publisher","first-page":"e4066","DOI":"10.1210\/clinem\/dgaa595","volume":"105","author":"K Nanba","year":"2020","unstructured":"Nanba, K. et al. Prevalence of somatic mutations in aldosterone-producing adenomas in Japanese patients. J. Clin. Endocrinol. Metab. 105, e4066\u2013e4073 (2020).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"714_CR35","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.125.25855","volume":"83","author":"AJ Newman","year":"2026","unstructured":"Newman, A. J. et al. Impact of age, sex, and race on primary aldosteronism test interpretations. Hypertension 83, e25855 (2026).","journal-title":"Hypertension"},{"key":"714_CR36","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1210\/clinem\/dgad515","volume":"109","author":"N Bechmann","year":"2024","unstructured":"Bechmann, N. et al. Asymmetric adrenals: sexual dimorphism of adrenal tumors. J. Clin. Endocrinol. Metab. 109, 471\u2013482 (2024).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"714_CR37","doi-asserted-by":"publisher","first-page":"R1","DOI":"10.1093\/ejendo\/lvaf088","volume":"192","author":"O Suntornlohanakul","year":"2025","unstructured":"Suntornlohanakul, O., Ronchi, C. L., Arlt, W. & Prete, A. Sexual dimorphism in benign adrenocortical tumours. Eur. J. Endocrinol. 192, R1\u2013R12 (2025). A review highlighting sex differences in the prevalence of various benign adrenal tumours, including those causing PA in humans.","journal-title":"Eur. J. Endocrinol."},{"key":"714_CR38","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1161\/HYPERTENSIONAHA.119.13006","volume":"74","author":"H Akasaka","year":"2019","unstructured":"Akasaka, H. et al. Sex difference in the association between subtype distribution and age at diagnosis in patients with primary aldosteronism. Hypertension 74, 368\u2013374 (2019).","journal-title":"Hypertension"},{"key":"714_CR39","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1038\/s41371-020-0336-2","volume":"34","author":"R Libianto","year":"2020","unstructured":"Libianto, R., Fuller, P. J., Young, M. J. & Yang, J. Primary aldosteronism is a public health issue: challenges and opportunities. J. Hum. Hypertens. 34, 478\u2013486 (2020).","journal-title":"J. Hum. Hypertens."},{"key":"714_CR40","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1161\/HYPERTENSIONAHA.125.24648","volume":"82","author":"JM Brown","year":"2025","unstructured":"Brown, J. M. et al. Nationwide, pragmatic, direct-to-patient primary aldosteronism testing program. Hypertension 82, 977\u2013988 (2025).","journal-title":"Hypertension"},{"key":"714_CR41","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1210\/endrev\/bnac011","volume":"43","author":"L Lenzini","year":"2022","unstructured":"Lenzini, L., Caroccia, B., Seccia, T. M. & Rossi, G. P. Peptidergic G protein-coupled receptor regulation of adrenal function: bench to bedside and back. Endocr. Rev. 43, 1038\u20131050 (2022).","journal-title":"Endocr. Rev."},{"key":"714_CR42","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1210\/clinem\/dgaa484","volume":"106","author":"TA Williams","year":"2021","unstructured":"Williams, T. A. et al. International histopathology consensus for unilateral primary aldosteronism. J. Clin. Endocrinol. Metab. 106, 42\u201354 (2021). A consensus that provides a standardized framework to classify aldosterone-producing adrenal lesions, which helps improve the interpretation of disease mechanisms and surgical outcomes.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"714_CR43","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s12022-022-09710-8","volume":"33","author":"O Mete","year":"2022","unstructured":"Mete, O. et al. Overview of the 2022 WHO classification of adrenal cortical tumors. Endocr. Pathol. 33, 155\u2013196 (2022).","journal-title":"Endocr. Pathol."},{"key":"714_CR44","unstructured":"WHO Classification of Tumours Editorial Board (eds) WHO Classification of Tumours: Endocrine and Neuroendocrine Tumours 5th edn (IARC, 2025)."},{"key":"714_CR45","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-025-03156-8","volume":"43","author":"F Arcidiacono","year":"2025","unstructured":"Arcidiacono, F. et al. Characteristic of aldosterone-producing adrenocortical carcinoma: review of the literature. Med. Oncol. 43, 56 (2025).","journal-title":"Med. Oncol."},{"key":"714_CR46","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/s41574-020-0382-4","volume":"16","author":"MC Zennaro","year":"2020","unstructured":"Zennaro, M. C., Boulkroun, S. & Fernandes-Rosa, F. L. Pathogenesis and treatment of primary aldosteronism. Nat. Rev. Endocrinol. 16, 578\u2013589 (2020).","journal-title":"Nat. Rev. Endocrinol."},{"key":"714_CR47","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.126.26225","volume":"83","author":"Y Pang","year":"2026","unstructured":"Pang, Y., Sun, Z. & Williams, T. A. Histopathology and molecular profiling of primary aldosteronism. Hypertension 83, e26225 (2026).","journal-title":"Hypertension"},{"key":"714_CR48","doi-asserted-by":"publisher","DOI":"10.1530\/JOE-22-0249","volume":"259","author":"J Yang","year":"2023","unstructured":"Yang, J., Young, M. J., Cole, T. J. & Fuller, P. J. Mineralocorticoid receptor signalling in primary aldosteronism. J. Endocrinol. 259, e220249 (2023). A review of experimental and clinical evidence demonstrating how aldosterone excess causes cardiovascular, renal and metabolic injury through the widely expressed mineralocorticoid receptor.","journal-title":"J. Endocrinol."},{"key":"714_CR49","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1038\/s41440-025-02270-4","volume":"48","author":"X Bu","year":"2025","unstructured":"Bu, X. et al. High salt intake exacerbates aldosterone-related target organ damage in patients with primary aldosteronism. Hypertens. Res. 48, 2339\u20132348 (2025).","journal-title":"Hypertens. Res."},{"key":"714_CR50","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s11886-019-1185-x","volume":"21","author":"GL Hundemer","year":"2019","unstructured":"Hundemer, G. L. Primary aldosteronism: cardiovascular outcomes pre- and post-treatment. Curr. Cardiol. Rep. 21, 93 (2019).","journal-title":"Curr. Cardiol. Rep."},{"key":"714_CR51","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1093\/ejendo\/lvae041","volume":"190","author":"P Mulatero","year":"2024","unstructured":"Mulatero, P. et al. Familial hyperaldosteronism: an European Reference Network on Rare Endocrine Conditions clinical practice guideline. Eur. J. Endocrinol. 190, G1\u2013G14 (2024). An informative clinical practice from the European Reference Network on Rare Endocrine Conditions on familial hyperaldosteronism.","journal-title":"Eur. J. Endocrinol."},{"key":"714_CR52","first-page":"1109","volume":"95","author":"DJ Sutherland","year":"1966","unstructured":"Sutherland, D. J., Ruse, J. L. & Laidlaw, J. C. Hypertension, increased aldosterone secretion and low plasma renin activity relieved by dexamethasone. Can. Med. Assoc. J. 95, 1109\u20131119 (1966).","journal-title":"Can. Med. Assoc. J."},{"key":"714_CR53","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1210\/jcem-59-5-1022","volume":"59","author":"CE Gomez-Sanchez","year":"1984","unstructured":"Gomez-Sanchez, C. E. et al. Elevated urinary excretion of 18-oxocortisol in glucocorticoid-suppressible aldosteronism. J. Clin. Endocrinol. Metab. 59, 1022\u20131024 (1984).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"714_CR54","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/355262a0","volume":"355","author":"RP Lifton","year":"1992","unstructured":"Lifton, R. P. et al. A chimaeric 11\u03b2-hydroxylase\/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 355, 262\u2013265 (1992).","journal-title":"Nature"},{"key":"714_CR55","doi-asserted-by":"publisher","first-page":"3117","DOI":"10.1210\/jc.2008-0594","volume":"93","author":"DS Geller","year":"2008","unstructured":"Geller, D. S. et al. A novel form of human mendelian hypertension featuring nonglucocorticoid-remediable aldosteronism. J. Clin. Endocrinol. Metab. 93, 3117\u20133123 (2008).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"714_CR56","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/s41588-018-0053-8","volume":"50","author":"FL Fernandes-Rosa","year":"2018","unstructured":"Fernandes-Rosa, F. L. et al. A gain-of-function mutation in the CLCN2 chloride channel gene causes primary aldosteronism. Nat. Genet. 50, 355\u2013361 (2018).","journal-title":"Nat. Genet."},{"key":"714_CR57","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41588-018-0048-5","volume":"50","author":"UI Scholl","year":"2018","unstructured":"Scholl, U. I. et al. CLCN2 chloride channel mutations in familial hyperaldosteronism type II. Nat. Genet. 50, 349\u2013354 (2018).","journal-title":"Nat. Genet."},{"key":"714_CR58","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1126\/science.1198785","volume":"331","author":"M Choi","year":"2011","unstructured":"Choi, M. et al. K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science 331, 768\u2013772 (2011). The first identification of mutations in PA driver genes, either somatically in some APAs or germline in hereditary familial hyperaldosteronism type III.","journal-title":"Science"},{"key":"714_CR59","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.06315","volume":"4","author":"UI Scholl","year":"2015","unstructured":"Scholl, U. I. et al. Recurrent gain of function mutation in calcium channel CACNA1H causes early-onset hypertension with primary aldosteronism. eLife 4, e06315 (2015).","journal-title":"eLife"},{"key":"714_CR60","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.ebiom.2016.10.002","volume":"13","author":"G Daniil","year":"2016","unstructured":"Daniil, G. et al. CACNA1H mutations are associated with different forms of primary aldosteronism. eBioMedicine 13, 225\u2013236 (2016).","journal-title":"eBioMedicine"},{"key":"714_CR61","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1038\/ng.2695","volume":"45","author":"UI Scholl","year":"2013","unstructured":"Scholl, U. I. et al. Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism. Nat. Genet. 45, 1050\u20131054 (2013).","journal-title":"Nat. Genet."},{"key":"714_CR62","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1161\/01.HYP.31.1.445","volume":"31","author":"WR Litchfield","year":"1998","unstructured":"Litchfield, W. R., Anderson, B. F., Weiss, R. J., Lifton, R. P. & Dluhy, R. G. Intracranial aneurysm and hemorrhagic stroke in glucocorticoid-remediable aldosteronism. Hypertension 31, 445\u2013450 (1998).","journal-title":"Hypertension"},{"key":"714_CR63","doi-asserted-by":"publisher","first-page":"5070","DOI":"10.1210\/jc.2005-0681","volume":"90","author":"M Stowasser","year":"2005","unstructured":"Stowasser, M. et al. Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I. J. Clin. Endocrinol. Metab. 90, 5070\u20135076 (2005).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"714_CR64","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1038\/ng.2716","volume":"45","author":"EA Azizan","year":"2013","unstructured":"Azizan, E. A. et al. Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension. Nat. Genet. 45, 1055\u20131060 (2013).","journal-title":"Nat. Genet."},{"key":"714_CR65","doi-asserted-by":"publisher","first-page":"K37","DOI":"10.1530\/EJE-19-0377","volume":"181","author":"RK Dutta","year":"2019","unstructured":"Dutta, R. K. et al. A somatic mutation in CLCN2 identified in a sporadic aldosterone-producing adenoma. Eur. J. Endocrinol. 181, K37\u2013K41 (2019).","journal-title":"Eur. J. Endocrinol."},{"key":"714_CR66","doi-asserted-by":"publisher","first-page":"bvaa123","DOI":"10.1210\/jendso\/bvaa123","volume":"4","author":"J Rege","year":"2020","unstructured":"Rege, J. et al. Identification of somatic mutations in CLCN2 in aldosterone-producing adenomas. J. Endocr. Soc. 4, bvaa123 (2020).","journal-title":"J. Endocr. Soc."},{"key":"714_CR67","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1161\/HYPERTENSIONAHA.119.14349","volume":"75","author":"K Nanba","year":"2020","unstructured":"Nanba, K. et al. Somatic CACNA1H mutation as a cause of aldosterone-producing adenoma. Hypertension 75, 645\u2013649 (2020).","journal-title":"Hypertension"},{"key":"714_CR68","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/ng.2550","volume":"45","author":"F Beuschlein","year":"2013","unstructured":"Beuschlein, F. et al. Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension. Nat. Genet. 45, 440\u2013444 (2013).","journal-title":"Nat. Genet."},{"key":"714_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/srep19546","volume":"6","author":"T Akerstrom","year":"2016","unstructured":"\u00c5kerstr\u00f6m, T. et al. Activating mutations in CTNNB1 in aldosterone producing adenomas. Sci. Rep. 6, 19546 (2016).","journal-title":"Sci. Rep."},{"key":"714_CR70","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1038\/s41588-021-00906-y","volume":"53","author":"J Zhou","year":"2021","unstructured":"Zhou, J. et al. Somatic mutations of GNA11 and GNAQ in CTNNB1-mutant aldosterone-producing adenomas presenting in puberty, pregnancy or menopause. Nat. Genet. 53, 1360\u20131372 (2021).","journal-title":"Nat. Genet."},{"key":"714_CR71","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1038\/s41588-023-01498-5","volume":"55","author":"J Rege","year":"2023","unstructured":"Rege, J. et al. Somatic SLC30A1 mutations altering zinc transporter ZnT1 cause aldosterone-producing adenomas and primary aldosteronism. Nat. Genet. 55, 1623\u20131631 (2023).","journal-title":"Nat. Genet."},{"key":"714_CR72","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1038\/s41588-023-01403-0","volume":"55","author":"X Wu","year":"2023","unstructured":"Wu, X. et al. Somatic mutations of CADM1 in aldosterone-producing adenomas and gap junction-dependent regulation of aldosterone production. Nat. Genet. 55, 1009\u20131021 (2023).","journal-title":"Nat. Genet."},{"key":"714_CR73","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1161\/HYPERTENSIONAHA.125.24909","volume":"82","author":"D van Rooyen","year":"2025","unstructured":"van Rooyen, D. et al. Somatic mutations in MCOLN3 are associated with aldosterone-producing adenomas. Hypertension 82, 1778\u20131788 (2025).","journal-title":"Hypertension"},{"key":"714_CR74","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1161\/HYPERTENSIONAHA.114.03419","volume":"64","author":"FL Fernandes-Rosa","year":"2014","unstructured":"Fernandes-Rosa, F. L. et al. Genetic spectrum and clinical correlates of somatic mutations in aldosterone-producing adenoma. Hypertension 64, 354\u2013361 (2014). This multicentre study, investigating a very large number of patients with APA, establishes the clinical and molecular correlates of somatic mutations in patients with PA.","journal-title":"Hypertension"},{"key":"714_CR75","doi-asserted-by":"publisher","first-page":"E1089","DOI":"10.1210\/jc.2015-2149","volume":"100","author":"L Lenzini","year":"2015","unstructured":"Lenzini, L. et al. A meta-analysis of somatic KCNJ5 K+ channel mutations in 1636 patients with an aldosterone-producing adenoma. J. Clin. Endocrinol. Metab. 100, E1089\u2013E1095 (2015).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"714_CR76","doi-asserted-by":"publisher","DOI":"10.1038\/srep11396","volume":"5","author":"VC Wu","year":"2015","unstructured":"Wu, V. C. et al. Prevalence and clinical correlates of somatic mutation in aldosterone producing adenoma-Taiwanese population. Sci. Rep. 5, 11396 (2015).","journal-title":"Sci. Rep."},{"key":"714_CR77","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1507\/endocrj.EJ16-0243","volume":"64","author":"T Okamura","year":"2017","unstructured":"Okamura, T. et al. Characteristics of Japanese aldosterone-producing adenomas with KCNJ5 mutations. Endocr. J. 64, 39\u201347 (2017).","journal-title":"Endocr. J."},{"key":"714_CR78","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1111\/cen.12873","volume":"83","author":"UI Scholl","year":"2015","unstructured":"Scholl, U. I. et al. Novel somatic mutations in primary hyperaldosteronism are related to the clinical, radiological and pathological phenotype. Clin. Endocrinol. 83, 779\u2013789 (2015).","journal-title":"Clin. Endocrinol."},{"key":"714_CR79","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1161\/HYPERTENSIONAHA.115.06186","volume":"67","author":"TA Williams","year":"2016","unstructured":"Williams, T. A. et al. Genotype-specific steroid profiles associated with aldosterone-producing adenomas. Hypertension 67, 139\u2013145 (2016).","journal-title":"Hypertension"},{"key":"714_CR80","doi-asserted-by":"publisher","first-page":"e282","DOI":"10.1210\/clinem\/dgz235","volume":"105","author":"Y Ono","year":"2020","unstructured":"Ono, Y. et al. Histological characterization of aldosterone-producing adrenocortical adenomas with different somatic mutations. J. Clin. Endocrinol. Metab. 105, e282\u2013e289 (2020).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"714_CR81","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1161\/HYPERTENSIONAHA.119.14177","volume":"75","author":"K De Sousa","year":"2020","unstructured":"De Sousa, K. et al. Genetic, cellular, and molecular heterogeneity in adrenals with aldosterone-producing adenoma. Hypertension 75, 1034\u20131044 (2020).","journal-title":"Hypertension"},{"key":"714_CR82","doi-asserted-by":"publisher","first-page":"3","DOI":"10.21037\/gs.2019.10.22","volume":"9","author":"J Rege","year":"2020","unstructured":"Rege, J., Turcu, A. F. & Rainey, W. E. Primary aldosteronism diagnostics: KCNJ5 mutations and hybrid steroid synthesis in aldosterone-producing adenomas. Gland. Surg. 9, 3\u201313 (2020).","journal-title":"Gland. Surg."},{"key":"714_CR83","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1161\/CIRCULATIONAHA.122.062349","volume":"147","author":"T Naito","year":"2023","unstructured":"Naito, T. et al. Genetic risk of primary aldosteronism and its contribution to hypertension: a cross-ancestry meta-analysis of genome-wide association studies. Circulation 147, 1097\u20131109 (2023).","journal-title":"Circulation"},{"key":"714_CR84","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.034180","volume":"13","author":"K Inoue","year":"2024","unstructured":"Inoue, K. et al. Primary aldosteronism and risk of cardiovascular outcomes: genome-wide association and mendelian randomization study. J. Am. Heart Assoc. 13, e034180 (2024).","journal-title":"J. Am. Heart Assoc."},{"key":"714_CR85","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32896-8","volume":"13","author":"E Le Floch","year":"2022","unstructured":"Le Floch, E. et al. Identification of risk loci for primary aldosteronism in genome-wide association studies. Nat. Commun. 13, 5198 (2022).","journal-title":"Nat. Commun."},{"key":"714_CR86","doi-asserted-by":"publisher","unstructured":"Borges, K. S. et al. Non-canonical Wnt signaling triggered by WNT2B drives adrenal aldosterone production. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2024.08.23.609423 (2024).","DOI":"10.1101\/2024.08.23.609423"},{"key":"714_CR87","doi-asserted-by":"publisher","unstructured":"Parisien-La Salle, S. et al. The evolution of primary aldosteronism and the role of Norrin. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2025.06.05.25329066 (2025).","DOI":"10.1101\/2025.06.05.25329066"},{"key":"714_CR88","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/bs.vh.2018.10.001","volume":"109","author":"H Lefebvre","year":"2019","unstructured":"Lefebvre, H. et al. Paracrine regulation of aldosterone secretion in physiological and pathophysiological conditions. Vitam. Horm. 109, 303\u2013339 (2019).","journal-title":"Vitam. Horm."},{"key":"714_CR89","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/S2213-8587(24)00200-6","volume":"12","author":"A Lacroix","year":"2024","unstructured":"Lacroix, A. et al. Aberrant hormone receptors regulate a wide spectrum of endocrine tumors. Lancet Diabetes Endocrinol. 12, 837\u2013855 (2024).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"714_CR90","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1210\/clinem\/dgaa703","volume":"106","author":"M St-Jean","year":"2021","unstructured":"St-Jean, M., Bourdeau, I., Martin, M. & Lacroix, A. Aldosterone is aberrantly regulated by various stimuli in a high proportion of patients with primary aldosteronism. J. Clin. Endocrinol. Metab. 106, e45\u2013e60 (2021). A systematic study of 43 patients with PA demonstrating that up to four different aberrant responses of aldosterone followed various activations of diverse ligand\u2013GPCR systems in up to 85% of patients with APA or bilateral PA.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"714_CR91","doi-asserted-by":"publisher","first-page":"72","DOI":"10.3389\/fendo.2016.00072","volume":"7","author":"N El Ghorayeb","year":"2016","unstructured":"El Ghorayeb, N., Bourdeau, I. & Lacroix, A. Role of ACTH and other hormones in the regulation of aldosterone production in primary aldosteronism. Front. Endocrinol. 7, 72 (2016).","journal-title":"Front. Endocrinol."},{"key":"714_CR92","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3389\/fendo.2016.00040","volume":"7","author":"JW Funder","year":"2016","unstructured":"Funder, J. W. The potential of ACTH in the genesis of primary aldosteronism. Front. Endocrinol. 7, 40 (2016).","journal-title":"Front. Endocrinol."},{"key":"714_CR93","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1210\/clinem\/dgae145","volume":"109","author":"WW Parksook","year":"2024","unstructured":"Parksook, W. W. et al. The spectrum of dysregulated aldosterone production: an international human physiology study. J. Clin. Endocrinol. Metab. 109, 2220\u20132232 (2024).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"714_CR94","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1161\/HYPERTENSIONAHA.124.24153","volume":"82","author":"JM Brown","year":"2025","unstructured":"Brown, J. M. et al. Characterizing the origins of primary aldosteronism. Hypertension 82, 306\u2013318 (2025).","journal-title":"Hypertension"},{"key":"714_CR95","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1530\/EJE-08-0711","volume":"160","author":"O Zwermann","year":"2009","unstructured":"Zwermann, O., Suttmann, Y., Bidlingmaier, M., Beuschlein, F. & Reincke, M. Screening for membrane hormone receptor expression in primary aldosteronism. Eur. J. Endocrinol. 160, 443\u2013451 (2009). Demonstration of the variable aberrant expression of various GPCRs in APA, including in particular MC2R and HT4R.","journal-title":"Eur. J. Endocrinol."},{"key":"714_CR96","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1530\/EJE-15-0148","volume":"173","author":"M Murakami","year":"2015","unstructured":"Murakami, M. et al. Integration of transcriptome and methylome analysis of aldosterone-producing adenomas. Eur. J. Endocrinol. 173, 185\u2013195 (2015).","journal-title":"Eur. J. Endocrinol."},{"key":"714_CR97","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.surg.2017.09.032","volume":"163","author":"G Rossitto","year":"2018","unstructured":"Rossitto, G. et al. Subtyping of primary aldosteronism with adrenal vein sampling: hormone- and side-specific effects of cosyntropin and metoclopramide. Surgery 163, 789\u2013795 (2018).","journal-title":"Surgery"},{"key":"714_CR98","doi-asserted-by":"publisher","first-page":"D15","DOI":"10.1530\/EJE-18-0844","volume":"181","author":"J Deinum","year":"2019","unstructured":"Deinum, J., Groenewoud, H., van der Wilt, G. J., Lenzini, L. & Rossi, G. P. Adrenal venous sampling: cosyntropin stimulation or not? Eur. J. Endocrinol. 181, D15\u2013D26 (2019).","journal-title":"Eur. J. Endocrinol."},{"key":"714_CR99","doi-asserted-by":"publisher","first-page":"644382","DOI":"10.3389\/fendo.2021.644382","volume":"12","author":"JS Lim","year":"2021","unstructured":"Lim, J. S., Plaska, S. W., Rege, J., Rainey, W. E. & Turcu, A. F. Aldosterone-regulating receptors and aldosterone-driver somatic mutations. Front. Endocrinol. 12, 644382 (2021).","journal-title":"Front. Endocrinol."},{"key":"714_CR100","doi-asserted-by":"publisher","first-page":"5867","DOI":"10.1210\/jc.2019-01182","volume":"104","author":"T Wannachalee","year":"2019","unstructured":"Wannachalee, T. et al. Three discrete patterns of primary aldosteronism lateralization in response to cosyntropin during adrenal vein sampling. J. Clin. Endocrinol. Metab. 104, 5867\u20135876 (2019). Study demonstrating variable responses to cosyntropin bolus during AVS: most patients with KCNJ5 mutations had descending lateralization index, whereas those with ATP1A1 and ATP2B3 mutations had ascending lateralization index after cosyntropin stimulation.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"714_CR101","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1210\/clinem\/dgab707","volume":"107","author":"K De Sousa","year":"2022","unstructured":"De Sousa, K. et al. Colocalization of Wnt\/\u03b2-catenin and ACTH signaling pathways and paracrine regulation in aldosterone-producing adenoma. J. Clin. Endocrinol. Metab. 107, 419\u2013434 (2022).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"714_CR102","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1210\/jcem.87.3.8327","volume":"87","author":"H Lefebvre","year":"2002","unstructured":"Lefebvre, H. et al. Characterization of serotonin4 receptors in adrenocortical aldosterone-producing adenomas: in vivo and in vitro studies. J. Clin. Endocrinol. Metab. 87, 1211\u20131216 (2002).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"714_CR103","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1530\/eje.1.02051","volume":"153","author":"D Cartier","year":"2005","unstructured":"Cartier, D. et al. Expression profile of serotonin4 (5-HT4) receptors in adrenocortical aldosterone-producing adenomas. Eur. J. Endocrinol. 153, 939\u2013947 (2005).","journal-title":"Eur. J. Endocrinol."},{"key":"714_CR104","doi-asserted-by":"publisher","first-page":"E550","DOI":"10.1210\/jc.2014-3660","volume":"100","author":"C Duparc","year":"2015","unstructured":"Duparc, C. et al. Mast cell hyperplasia is associated with aldosterone hypersecretion in a subset of aldosterone-producing adenomas. J. Clin. Endocrinol. Metab. 100, E550\u2013E560 (2015). Study demonstrating that APA tissues commonly contain numerous mast cells that may influence aldosterone secretion through the local release of regulatory factors activating overexpressed HT4R.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"714_CR105","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.mce.2016.06.015","volume":"434","author":"A Naccache","year":"2016","unstructured":"Naccache, A. et al. Temporal and spatial distribution of mast cells and steroidogenic enzymes in the human fetal adrenal. Mol. Cell Endocrinol. 434, 69\u201380 (2016).","journal-title":"Mol. Cell Endocrinol."},{"key":"714_CR106","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1210\/jc.2008-1340","volume":"94","author":"A Lampron","year":"2009","unstructured":"Lampron, A. et al. Regulation of aldosterone secretion by several aberrant receptors including for glucose-dependent insulinotropic peptide in a patient with an aldosteronoma. J. Clin. Endocrinol. Metab. 94, 750\u2013756 (2009).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"714_CR107","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.mce.2017.08.019","volume":"461","author":"K Itcho","year":"2018","unstructured":"Itcho, K. et al. Aberrant G protein-receptor expression is associated with DNA methylation in aldosterone-producing adenoma. Mol. Cell Endocrinol. 461, 100\u2013104 (2018).","journal-title":"Mol. Cell Endocrinol."},{"key":"714_CR108","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1210\/jc.2005-1298","volume":"91","author":"K Saner-Amigh","year":"2006","unstructured":"Saner-Amigh, K. et al. Elevated expression of luteinizing hormone receptor in aldosterone-producing adenomas. J. Clin. Endocrinol. Metab. 91, 1136\u20131142 (2006).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"714_CR109","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1161\/HYPERTENSIONAHA.116.08033","volume":"68","author":"J Zhou","year":"2016","unstructured":"Zhou, J. et al. Transcriptome pathway analysis of pathological and physiological aldosterone-producing human tissues. Hypertension 68, 1424\u20131431 (2016).","journal-title":"Hypertension"},{"key":"714_CR110","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1530\/EJE-10-0879","volume":"164","author":"NM Albiger","year":"2011","unstructured":"Albiger, N. M. et al. A case of primary aldosteronism in pregnancy: do LH and GNRH receptors have a potential role in regulating aldosterone secretion?\u00a0Eur. J. Endocrinol. 164, 405\u2013412 (2011).","journal-title":"Eur. J. Endocrinol."},{"key":"714_CR111","doi-asserted-by":"publisher","first-page":"1153374","DOI":"10.3389\/fendo.2023.1153374","volume":"14","author":"F Castinetti","year":"2023","unstructured":"Castinetti, F., Guerin, C., Louiset, E. & Lacroix, A. HCG-responsive aldosteronoma with transient secretion during pregnancy confirmed through HCG-stimulated adrenal venous sampling. Front. Endocrinol. 14, 1153374 (2023). A dramatic example showing that a small APA harbouring ectopic LHCGR can be silent outside of pregnancy and become florid during pregnancy, when physiologically high levels of hCG activate the ectopic receptor.","journal-title":"Front. Endocrinol."},{"key":"714_CR112","first-page":"1494","volume":"374","author":"AE Teo","year":"2016","unstructured":"Teo, A. E. & Brown, M. J. Pregnancy, primary aldosteronism, and somatic CTNNB1 mutations. N. Engl. J. Med. 374, 1494 (2016).","journal-title":"N. Engl. J. Med."},{"key":"714_CR113","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1210\/jc.2018-00087","volume":"103","author":"N Gagnon","year":"2018","unstructured":"Gagnon, N. et al. Genetic characterization of GnRH\/LH-responsive primary aldosteronism. J. Clin. Endocrinol. Metab. 103, 2926\u20132935 (2018).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"714_CR114","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1093\/hmg\/ddt484","volume":"23","author":"A Berthon","year":"2014","unstructured":"Berthon, A. et al. WNT\/\u03b2-catenin signalling is activated in aldosterone-producing adenomas and controls aldosterone production. Hum. Mol. Genet. 23, 889\u2013905 (2014).","journal-title":"Hum. Mol. Genet."},{"key":"714_CR115","doi-asserted-by":"publisher","first-page":"332","DOI":"10.3803\/EnM.2017.32.3.332","volume":"32","author":"J-J Wang","year":"2017","unstructured":"Wang, J.-J., Peng, K.-Y., Wu, V.-C., Tseng, F.-Y. & Wu, K.-D. CTNNB1 mutation in aldosterone producing adenoma. Endocrinol. Metab. 32, 332\u2013338 (2017). This study examined CTNNB1 mutations (encoding \u03b2-catenin) in APAs, confirming that they occur in a subset of APAs and suggesting that activation of the WNT\u2013\u03b2-catenin signalling pathway is involved in PA pathogenesis.","journal-title":"Endocrinol. Metab."},{"key":"714_CR116","doi-asserted-by":"publisher","first-page":"e865","DOI":"10.1210\/clinem\/dgab611","volume":"107","author":"CT Fuss","year":"2022","unstructured":"Fuss, C. T., Brohm, K., Fassnacht, M., Kroiss, M. & Hahner, S. Reassessment of postural stimulation testing as a simple tool to identify a subgroup of patients with unilateral primary aldosteronism. J. Clin. Endocrinol. Metab. 107, e865\u2013e873 (2022).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"714_CR117","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/j.1365-2265.2011.04202.x","volume":"76","author":"JH Lau","year":"2012","unstructured":"Lau, J. H. et al. A prospective evaluation of postural stimulation testing, computed tomography and adrenal vein sampling in the differential diagnosis of primary aldosteronism. Clin. Endocrinol. 76, 182\u2013188 (2012).","journal-title":"Clin. Endocrinol."},{"key":"714_CR118","doi-asserted-by":"publisher","first-page":"bvae155","DOI":"10.1210\/jendso\/bvae155","volume":"8","author":"N Younes","year":"2024","unstructured":"Younes, N. et al. Usefulness of the upright posture test in the diagnosis of primary aldosteronism. J. Endocr. Soc. 8, bvae155 (2024). Renin-independent aldosterone secretion can be frequently identified by 2-h upright posture test in patients suspected of PA, but in whom intravenous or oral saline suppression tests yielded false negative suppression of aldosterone levels.","journal-title":"J. Endocr. Soc."},{"key":"714_CR119","doi-asserted-by":"publisher","first-page":"e3832","DOI":"10.1210\/clinem\/dgaf129","volume":"110","author":"S Parisien-La Salle","year":"2025","unstructured":"Parisien-La Salle, S. et al. Subclinical primary aldosteronism is characterized by maladaptive natriuretic peptide and adrenal hormonal physiology. J. Clin. Endocrinol. Metab. 110, e3832\u2013e3840 (2025). The pathophysiological continuum of subclinical PA in people with normotension is characterized by natriuretic peptide insufficiency and heightened aldosterone responses to both angiotensin II and ACTH. These early maladaptive hormonal changes provide mechanistic explanations for the role of subclinical PA in the pathogenesis of hypertension.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"714_CR120","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1161\/HYPERTENSIONAHA.120.16429","volume":"77","author":"N Yozamp","year":"2021","unstructured":"Yozamp, N. et al. Intraindividual variability of aldosterone concentrations in primary aldosteronism: implications for case detection. Hypertension 77, 891\u2013899 (2021). Refs. 120\u2013122\u00a0demonstrate that significant intra-individual variability in plasma aldosterone concentration, direct renin concentration and, hence, ARR occurs in a large proportion of patients being investigated for PA. These findings support the need for at least two ARRs before PA is excluded or further investigated.","journal-title":"Hypertension"},{"key":"714_CR121","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1210\/clinem\/dgac568","volume":"108","author":"E Ng","year":"2022","unstructured":"Ng, E. et al. Aldosterone, renin, and aldosterone-to-renin ratio variability in screening for primary aldosteronism. J. Clin. Endocrinol. Metab. 108, 33\u201341 (2022).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"714_CR122","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1210\/clinem\/dgac679","volume":"108","author":"AAW Maciel","year":"2023","unstructured":"Maciel, A. A. W. et al. Intra-individual variability of serum aldosterone and implications for primary aldosteronism screening. J. Clin. Endocrinol. Metab. 108, 1143\u20131153 (2023).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"714_CR123","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1146\/annurev-physiol-060821-013950","volume":"84","author":"J Barrera-Chimal","year":"2022","unstructured":"Barrera-Chimal, J., Bonnard, B. & Jaisser, F. Roles of mineralocorticoid receptors in cardiovascular and cardiorenal diseases. Annu. Rev. Physiol. 84, 585\u2013610 (2022).","journal-title":"Annu. Rev. Physiol."},{"key":"714_CR124","doi-asserted-by":"publisher","first-page":"101762","DOI":"10.1016\/j.jacadv.2025.101762","volume":"4","author":"M Alfarano","year":"2025","unstructured":"Alfarano, M. et al. Aldosterone-related cardiovascular disease and benefits of mineralocorticoid receptor antagonists in clinical practice. JACC Adv. 4, 101762 (2025).","journal-title":"JACC Adv."},{"key":"714_CR125","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1161\/01.RES.0000159937.05502.d1","volume":"96","author":"IZ Jaffe","year":"2005","unstructured":"Jaffe, I. Z. & Mendelsohn, M. E. Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells. Circ. Res. 96, 643\u2013650 (2005).","journal-title":"Circ. Res."},{"key":"714_CR126","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1161\/CIRCRESAHA.108.174235","volume":"102","author":"M Caprio","year":"2008","unstructured":"Caprio, M. et al. Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion. Circ. Res. 102, 1359\u20131367 (2008).","journal-title":"Circ. Res."},{"key":"714_CR127","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.ijcard.2017.01.013","volume":"232","author":"V Marzolla","year":"2017","unstructured":"Marzolla, V. et al. Essential role of ICAM-1 in aldosterone-induced atherosclerosis. Int. J. Cardiol. 232, 233\u2013242 (2017).","journal-title":"Int. J. Cardiol."},{"key":"714_CR128","doi-asserted-by":"publisher","first-page":"313","DOI":"10.3389\/fphar.2017.00313","volume":"8","author":"GH Tesch","year":"2017","unstructured":"Tesch, G. H. & Young, M. J. Mineralocorticoid receptor signaling as a therapeutic target for renal and cardiac fibrosis. Front. Pharmacol. 8, 313 (2017).","journal-title":"Front. Pharmacol."},{"key":"714_CR129","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1159\/000480652","volume":"46","author":"Z Belden","year":"2017","unstructured":"Belden, Z., Deiuliis, J. A., Dobre, M. & Rajagopalan, S. The role of the mineralocorticoid receptor in inflammation: focus on kidney and vasculature. Am. J. Nephrol. 46, 298\u2013314 (2017).","journal-title":"Am. J. Nephrol."},{"key":"714_CR130","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.trsl.2019.03.004","volume":"209","author":"RT Cowling","year":"2019","unstructured":"Cowling, R. T., Kupsky, D., Kahn, A. M., Daniels, L. B. & Greenberg, B. H. Mechanisms of cardiac collagen deposition in experimental models and human disease. Transl. Res. 209, 138\u2013155 (2019).","journal-title":"Transl. Res."},{"key":"714_CR131","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/s41392-022-00972-6","volume":"7","author":"X He","year":"2022","unstructured":"He, X. et al. Signaling cascades in the failing heart and emerging therapeutic strategies. Signal. Transduct. Target. Ther. 7, 134 (2022).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"714_CR132","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.125.26187","volume":"83","author":"A Mamazhakypov","year":"2026","unstructured":"Mamazhakypov, A., Peyronnet, R. & Lother, A. Aldosterone and the mineralocorticoid receptor in atrial fibrillation. Hypertension 83, e26187 (2026).","journal-title":"Hypertension"},{"key":"714_CR133","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1161\/HYPERTENSIONAHA.121.17436","volume":"78","author":"H Ogata","year":"2021","unstructured":"Ogata, H. et al. Renal injuries in primary aldosteronism: quantitative histopathological analysis of 19 patients with primary adosteronism. Hypertension 78, 411\u2013421 (2021).","journal-title":"Hypertension"},{"key":"714_CR134","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.kisu.2021.11.006","volume":"12","author":"JM Luther","year":"2022","unstructured":"Luther, J. M. & Fogo, A. B. The role of mineralocorticoid receptor activation in kidney inflammation and fibrosis. Kidney Int. Suppl. 12, 63\u201368 (2022).","journal-title":"Kidney Int. Suppl."},{"key":"714_CR135","doi-asserted-by":"publisher","first-page":"3781","DOI":"10.1093\/eurheartj\/ehac352","volume":"43","author":"A Verma","year":"2022","unstructured":"Verma, A., Vaidya, A., Subudhi, S. & Waikar, S. S. Aldosterone in chronic kidney disease and renal outcomes. Eur. Heart J. 43, 3781\u20133791 (2022).","journal-title":"Eur. Heart J."},{"key":"714_CR136","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1177\/1358863X12450094","volume":"17","author":"MS Zhou","year":"2012","unstructured":"Zhou, M. S., Schulman, I. H. & Zeng, Q. Link between the renin-angiotensin system and insulin resistance: implications for cardiovascular disease. Vasc. Med. 17, 330\u2013341 (2012).","journal-title":"Vasc. Med."},{"key":"714_CR137","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1161\/HYPERTENSIONAHA.119.13922","volume":"75","author":"GK Adler","year":"2020","unstructured":"Adler, G. K. et al. Primary aldosteronism decreases insulin secretion and increases insulin clearance in humans. Hypertension 75, 1251\u20131259 (2020).","journal-title":"Hypertension"},{"key":"714_CR138","doi-asserted-by":"publisher","first-page":"R276","DOI":"10.1152\/ajpregu.00280.2020","volume":"320","author":"G Jia","year":"2021","unstructured":"Jia, G., Lockette, W. & Sowers, J. R. Mineralocorticoid receptors in the pathogenesis of insulin resistance and related disorders: from basic studies to clinical disease. Am. J. Physiol. Regul. Integr. Comp. Physiol. 320, R276\u2013R286 (2021).","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"714_CR139","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1097\/HJH.0000000000001361","volume":"35","author":"V-C Wu","year":"2017","unstructured":"Wu, V.-C. et al. Risk of new-onset diabetes mellitus in primary aldosteronism: a population study over 5 years. J. Hypertens. 35, 1698\u20131708 (2017). This large-scale population study demonstrated that patients with PA have a significantly increased risk of developing new-onset diabetes mellitus compared with matched patients with essential hypertension over 5 years.","journal-title":"J. Hypertens."},{"key":"714_CR140","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.93136","volume":"2","author":"W Arlt","year":"2017","unstructured":"Arlt, W. et al. Steroid metabolome analysis reveals prevalent glucocorticoid excess in primary aldosteronism. JCI Insight 2, e93136 (2017). Steroid metabolome analysis reveals prevalent glucocorticoid excess in primary aldosteronism.","journal-title":"JCI Insight"},{"key":"714_CR141","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7326\/0003-4819-44-1-1","volume":"44","author":"JW Conn","year":"1956","unstructured":"Conn, J. W. & Louis, L. H. Primary aldosteronism, a new clinical entity. Ann. Intern. Med. 44, 1\u201315 (1956).","journal-title":"Ann. Intern. Med."},{"key":"714_CR142","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1001\/jama.1964.03070160046009","volume":"190","author":"JW Conn","year":"1964","unstructured":"Conn, J. W. Plasma renin activity in primary aldosteronism. importance in differential diagnosis and in research of essential hypertension. JAMA 190, 222\u2013225 (1964).","journal-title":"JAMA"},{"key":"714_CR143","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1681\/ASN.2004100878","volume":"16","author":"J Ribstein","year":"2005","unstructured":"Ribstein, J., Du Cailar, G., Fesler, P. & Mimran, A. Relative glomerular hyperfiltration in primary aldosteronism. J. Am. Soc. Nephrol. 16, 1320\u20131325 (2005).","journal-title":"J. Am. Soc. Nephrol."},{"key":"714_CR144","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/HJH.0000000000002216","volume":"38","author":"S Monticone","year":"2020","unstructured":"Monticone, S. et al. Renal damage in primary aldosteronism: a systematic review and meta-analysis. J. Hypertens. 38, 3\u201312 (2020).","journal-title":"J. Hypertens."},{"key":"714_CR145","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s11906-012-0297-0","volume":"14","author":"UA Hawkins","year":"2012","unstructured":"Hawkins, U. A., Gomez-Sanchez, E. P., Gomez-Sanchez, C. M. & Gomez-Sanchez, C. E. The ubiquitous mineralocorticoid receptor: clinical implications. Curr. Hypertens. Rep. 14, 573\u2013580 (2012).","journal-title":"Curr. Hypertens. Rep."},{"key":"714_CR146","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1097\/00041552-200403000-00007","volume":"13","author":"EP Gomez-Sanchez","year":"2004","unstructured":"Gomez-Sanchez, E. P. Brain mineralocorticoid receptors: orchestrators of hypertension and end-organ disease. Curr. Opin. Nephrol. Hypertens. 13, 191\u2013196 (2004).","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"714_CR147","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.mce.2011.05.005","volume":"350","author":"EP Gomez-Sanchez","year":"2012","unstructured":"Gomez-Sanchez, E. P. & Gomez-Sanchez, C. E. Central regulation of blood pressure by the mineralocorticoid receptor. Mol. Cell. Endocrinol. 350, 289\u2013298 (2012).","journal-title":"Mol. Cell. Endocrinol."},{"key":"714_CR148","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1038\/nm.2891","volume":"18","author":"A McCurley","year":"2012","unstructured":"McCurley, A. et al. Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors. Nat. Med. 18, 1429\u20131433 (2012).","journal-title":"Nat. Med."},{"key":"714_CR149","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1161\/HYPERTENSIONAHA.112.194787","volume":"60","author":"P Raheja","year":"2012","unstructured":"Raheja, P. et al. Spironolactone prevents chlorthalidone-induced sympathetic activation and insulin resistance in hypertensive patients. Hypertension 60, 319\u2013325 (2012).","journal-title":"Hypertension"},{"key":"714_CR150","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1210\/jc.2008-2660","volume":"94","author":"DV Menon","year":"2009","unstructured":"Menon, D. V. et al. Differential effects of chlorthalidone versus spironolactone on muscle sympathetic nerve activity in hypertensive patients. J. Clin. Endocrinol. Metab. 94, 1361\u20131366 (2009).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"714_CR151","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","volume":"386","author":"B Williams","year":"2015","unstructured":"Williams, B. et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 386, 2059\u20132068 (2015).","journal-title":"Lancet"},{"key":"714_CR152","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1093\/eurheartj\/ehaf225","volume":"46","author":"M Kobayashi","year":"2025","unstructured":"Kobayashi, M. et al. Aldosterone-targeted therapies: early implementation in resistant hypertension and chronic kidney disease. Eur. Heart J. 46, 2618\u20132642 (2025).","journal-title":"Eur. Heart J."},{"key":"714_CR153","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1161\/HYPERTENSIONAHA.119.14063","volume":"75","author":"J Burrello","year":"2020","unstructured":"Burrello, J. et al. Prevalence of hypokalemia and primary aldosteronism in 5100 patients referred to a tertiary hypertension unit. Hypertension 75, 1025\u20131033 (2020). Hypokalaemia is present in only a minority of patients with PA, reinforcing the need for active screening for PA in people with hypertension, even if serum potassium is normal.","journal-title":"Hypertension"},{"key":"714_CR154","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1055\/a-1134-4980","volume":"52","author":"S Gruber","year":"2020","unstructured":"Gruber, S. & Beuschlein, F. Hypokalemia and the prevalence of primary aldosteronism. Horm. Metab. Res. 52, 347\u2013356 (2020).","journal-title":"Horm. Metab. Res."},{"key":"714_CR155","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.2215\/CJN.08580813","volume":"10","author":"BF Palmer","year":"2015","unstructured":"Palmer, B. F. Regulation of potassium homeostasis. Clin. J. Am. Soc. Nephrol. 10, 1050\u20131060 (2015).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"714_CR156","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.116.004667","volume":"10","author":"JN Weiss","year":"2017","unstructured":"Weiss, J. N., Qu, Z. & Shivkumar, K. Electrophysiology of hypokalemia and hyperkalemia. Circ. Arrhythm. Electrophysiol. 10, e004667 (2017).","journal-title":"Circ. Arrhythm. Electrophysiol."},{"key":"714_CR157","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/nrcardio.2012.3","volume":"9","author":"JR Giudicessi","year":"2012","unstructured":"Giudicessi, J. R. & Ackerman, M. J. Potassium-channel mutations and cardiac arrhythmias \u2014 diagnosis and therapy. Nat. Rev. Cardiol. 9, 319\u2013332 (2012).","journal-title":"Nat. Rev. Cardiol."},{"key":"714_CR158","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1161\/CIRCRESAHA.119.315641","volume":"126","author":"K Tazmini","year":"2020","unstructured":"Tazmini, K. et al. Hypokalemia promotes arrhythmia by distinct mechanisms in atrial and ventricular myocytes. Circ. Res. 126, 889\u2013906 (2020).","journal-title":"Circ. Res."},{"key":"714_CR159","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1210\/jc.2015-4061","volume":"101","author":"JW Funder","year":"2016","unstructured":"Funder, J. W. et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 101, 1889\u20131916 (2016).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"714_CR160","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1097\/HJH.0000000000002453","volume":"38","author":"T Unger","year":"2020","unstructured":"Unger, T. et al. 2020 International Society of Hypertension global hypertension practice guidelines. J. Hypertens. 38, 982\u20131004 (2020).","journal-title":"J. Hypertens."},{"key":"714_CR161","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/j.jacc.2022.08.714","volume":"80","author":"A Januszewicz","year":"2022","unstructured":"Januszewicz, A. et al. Cardiac phenotypes in secondary hypertension: JACC state-of-the-art review. J. Am. Coll. Cardiol. 80, 1480\u20131497 (2022).","journal-title":"J. Am. Coll. Cardiol."},{"key":"714_CR162","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1210\/clinem\/dgad044","volume":"108","author":"E Sconfienza","year":"2023","unstructured":"Sconfienza, E. et al. Prevalence of functioning adrenal incidentalomas: a systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 108, 1813\u20131823 (2023).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"714_CR163","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1097\/HJH.0000000000002250","volume":"38","author":"TM Seccia","year":"2020","unstructured":"Seccia, T. M. et al. Atrial fibrillation as presenting sign of primary aldosteronism: results of the Prospective Appraisal on the Prevalence of Primary Aldosteronism in Hypertensive (PAPPHY) study. J. Hypertens. 38, 332\u2013339 (2020).","journal-title":"J. Hypertens."},{"key":"714_CR164","doi-asserted-by":"publisher","first-page":"408","DOI":"10.5694\/mja2.51438","volume":"216","author":"R Libianto","year":"2022","unstructured":"Libianto, R. et al. Detecting primary aldosteronism in Australian primary care: a prospective study. Med. J. Aust. 216, 408\u2013412 (2022).","journal-title":"Med. J. Aust."},{"key":"714_CR165","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.1097\/CM9.0000000000003431","volume":"137","author":"Chinese Society of Cardiology, Chinese Medical Association, Hypertension Committee of Cross-Straits Medicine Exchange Association, Cardiovascular Disease Prevention and Rehabilitation Committee & Chinese Association of Rehabilitation Medicine","year":"2024","unstructured":"Chinese Society of Cardiology, Chinese Medical Association, Hypertension Committee of Cross-Straits Medicine Exchange Association, Cardiovascular Disease Prevention and Rehabilitation Committee & Chinese Association of Rehabilitation Medicine. Clinical practice guideline for the management of hypertension in China. Chin. Med J. 137, 2907\u20132952 (2024).","journal-title":"Chin. Med J."},{"key":"714_CR166","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1001\/archinte.1981.00340130033011","volume":"141","author":"K Hiramatsu","year":"1981","unstructured":"Hiramatsu, K. et al. A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients. Arch. Intern. Med. 141, 1589\u20131593 (1981).","journal-title":"Arch. Intern. Med."},{"key":"714_CR167","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1161\/HYPERTENSIONAHA.116.08793","volume":"69","author":"MM Beeftink","year":"2017","unstructured":"Beeftink, M. M. et al. Safety of temporary discontinuation of antihypertensive medication in patients with difficult-to-control hypertension. Hypertension 69, 927\u2013932 (2017).","journal-title":"Hypertension"},{"key":"714_CR168","doi-asserted-by":"publisher","first-page":"3965","DOI":"10.1210\/jc.2018-01041","volume":"103","author":"Z Guo","year":"2018","unstructured":"Guo, Z. et al. Aldosterone LC-MS\/MS assay-specific threshold values in screening and confirmatory testing for primary aldosteronism. J. Clin. Endocrinol. Metab. 103, 3965\u20133973 (2018).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"714_CR169","doi-asserted-by":"publisher","first-page":"bvac049","DOI":"10.1210\/jendso\/bvac049","volume":"6","author":"JM Brown","year":"2022","unstructured":"Brown, J. M. et al. Recalibrating interpretations of aldosterone assays across the physiologic range: immunoassay and liquid chromatography-tandem mass spectrometry measurements under multiple controlled conditions. J. Endocr. Soc. 6, bvac049 (2022).","journal-title":"J. Endocr. Soc."},{"key":"714_CR170","doi-asserted-by":"publisher","first-page":"bvae080","DOI":"10.1210\/jendso\/bvae080","volume":"8","author":"Y Ono","year":"2024","unstructured":"Ono, Y. et al. Screening cutoff values for the detection of aldosterone-producing adenoma by LC-MS\/MS and a novel noncompetitive CLEIA. J. Endocr. Soc. 8, bvae080 (2024).","journal-title":"J. Endocr. Soc."},{"key":"714_CR171","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1038\/s41440-024-01594-x","volume":"47","author":"Y Tezuka","year":"2024","unstructured":"Tezuka, Y. et al. Investigating the cut-off values of captopril challenge test for primary aldosteronism using the novel chemiluminescent enzyme immunoassay method: a retrospective cohort study. Hypertens. Res. 47, 1362\u20131371 (2024).","journal-title":"Hypertens. Res."},{"key":"714_CR172","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.4158\/EP-2020-0277","volume":"26","author":"Y Tezuka","year":"2020","unstructured":"Tezuka, Y. & Turcu, A. F. Mineralocorticoid receptor antagonists decrease the rates of positive screening for primary aldosteronism. Endocr. Pract. 26, 1416\u20131424 (2020).","journal-title":"Endocr. Pract."},{"key":"714_CR173","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1161\/01.HYP.0000038478.59760.41","volume":"40","author":"P Mulatero","year":"2002","unstructured":"Mulatero, P. et al. Drug effects on aldosterone\/plasma renin activity ratio in primary aldosteronism. Hypertension 40, 897\u2013902 (2002).","journal-title":"Hypertension"},{"key":"714_CR174","doi-asserted-by":"publisher","first-page":"127","DOI":"10.31128\/AJGP-07-19-4995","volume":"49","author":"T Gurgenci","year":"2020","unstructured":"Gurgenci, T., Geraghty, S., Wolley, M. & Yang, J. Screening for primary aldosteronism: how to adjust existing antihypertensive medications to avoid diagnostic errors. Aust. J. Gen. Pract. 49, 127\u2013131 (2020).","journal-title":"Aust. J. Gen. Pract."},{"key":"714_CR175","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1007\/s12020-024-03798-0","volume":"85","author":"JG Ruiz-S\u00e1nchez","year":"2024","unstructured":"Ruiz-S\u00e1nchez, J. G., Fern\u00e1ndez S\u00e1nchez, \u00c1. & Meneses, D. Feasibility of primary aldosteronism diagnosis in initial evaluation without medication withdrawal or confirmatory tests. Endocrine 85, 906\u2013915 (2024).","journal-title":"Endocrine"},{"key":"714_CR176","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1007\/s12020-023-03520-6","volume":"83","author":"X Li","year":"2024","unstructured":"Li, X. et al. Screening for primary aldosteronism on and off interfering medications. Endocrine 83, 178\u2013187 (2024).","journal-title":"Endocrine"},{"key":"714_CR177","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/cen.12882","volume":"84","author":"GA Browne","year":"2016","unstructured":"Browne, G. A., Griffin, T. P., O\u2019Shea, P. M. & Dennedy, M. C. \u03b2-Blocker withdrawal is preferable for accurate interpretation of the aldosterone-renin ratio in chronically treated hypertension. Clin. Endocrinol. 84, 325\u2013331 (2016).","journal-title":"Clin. Endocrinol."},{"key":"714_CR178","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1161\/HYPERTENSIONAHA.124.23029","volume":"81","author":"G Constantinescu","year":"2024","unstructured":"Constantinescu, G. et al. Steroidomics-based screening for primary aldosteronism: impact of antihypertensive drugs. Hypertension 81, 2060\u20132071 (2024).","journal-title":"Hypertension"},{"key":"714_CR179","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1161\/HYPERTENSIONAHA.120.14871","volume":"76","author":"Z Guo","year":"2020","unstructured":"Guo, Z. et al. Effects of ramipril on the aldosterone\/renin ratio and the aldosterone\/angiotensin II ratio in patients with primary aldosteronism. Hypertension 76, 488\u2013496 (2020).","journal-title":"Hypertension"},{"key":"714_CR180","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1093\/ejendo\/lvaf117","volume":"193","author":"M Murakami","year":"2025","unstructured":"Murakami, M. et al. Expert consensus on the primary aldosteronism severity classification and its strategic application in indicating adrenal venous sampling. Eur. J. Endocrinol. 193, 85\u201396 (2025). A global expert consensus-based classification for PA severity to improve clinical decision-making for indications for AVS for potentially surgically correctable PA.","journal-title":"Eur. J. Endocrinol."},{"key":"714_CR181","doi-asserted-by":"publisher","first-page":"e837","DOI":"10.1210\/clinem\/dgad451","volume":"109","author":"E Ng","year":"2024","unstructured":"Ng, E., Gwini, S. M., Zheng, W., Fuller, P. J. & Yang, J. Predicting bilateral subtypes of primary aldosteronism without adrenal vein sampling: a systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 109, e837\u2013e855 (2024).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"714_CR182","doi-asserted-by":"publisher","DOI":"10.1530\/EC-25-0339","volume":"14","author":"E Ng","year":"2025","unstructured":"Ng, E., Gwini, S. M., Zheng, W., Fuller, P. J. & Yang, J. Identifying unilateral aldosterone-producing adenomas using published algorithms and imaging: a systematic review and meta-analysis. Endocr. Connect. 14, e250339 (2025).","journal-title":"Endocr. Connect."},{"key":"714_CR183","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1161\/HYPERTENSIONAHA.122.19377","volume":"79","author":"AA Leung","year":"2022","unstructured":"Leung, A. A. et al. Performance of confirmatory tests for diagnosing primary aldosteronism: a systematic review and meta-analysis. Hypertension 79, 1835\u20131844 (2022). Comprehensive systematic review and meta-analysis of 55 studies pertaining to PA confirmatory tests showing a high risk of bias in most, high study heterogeneity and high probability of test accuracy overestimation.","journal-title":"Hypertension"},{"key":"714_CR184","doi-asserted-by":"publisher","first-page":"e2833","DOI":"10.1210\/clinem\/dgaf290","volume":"110","author":"MH Farah","year":"2025","unstructured":"Farah, M. H. et al. A systematic review supporting the Endocrine Society clinical practice guideline on management of primary aldosteronism. J. Clin. Endocrinol. Metab. 110, e2833\u2013e2844 (2025).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"714_CR185","doi-asserted-by":"publisher","first-page":"948","DOI":"10.7326\/ANNALS-24-03153","volume":"178","author":"AA Leung","year":"2025","unstructured":"Leung, A. A. et al. Confirmatory testing for primary aldosteronism: a study of diagnostic test accuracy. Ann. Intern. Med. 178, 948\u2013956 (2025). Prospective, blinded, diagnostic clinical trial demonstrating that response to seated saline suppression testing did not predict or associate with response to either medical or surgical therapy in patients with hypertension and high ARR.","journal-title":"Ann. Intern. Med."},{"key":"714_CR186","doi-asserted-by":"publisher","first-page":"4113","DOI":"10.1210\/jc.2018-01394","volume":"103","author":"M Stowasser","year":"2018","unstructured":"Stowasser, M. et al. Comparison of seated with recumbent saline suppression testing for the diagnosis of primary aldosteronism. J. Clin. Endocrinol. Metab. 103, 4113\u20134124 (2018). Seated intravenous saline suppression test is highly sensitive and superior to the previously used recumbent intravenous saline suppression test in identifying both unilateral and bilateral forms of PA defined by the fludrocortisone suppression test; however, the seated test still carries a 10\u201312% risk of false-negative response.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"714_CR187","doi-asserted-by":"publisher","DOI":"10.1093\/ejendo\/lvac003","volume":"188","author":"H Hashimura","year":"2023","unstructured":"Hashimura, H. et al. Saline suppression to distinguish the primary aldosteronism subtype: a diagnostic study. Eur. J. Endocrinol. 188, lvac003 (2023).","journal-title":"Eur. J. Endocrinol."},{"key":"714_CR188","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.125.26302","volume":"83","author":"M Stowasser","year":"2026","unstructured":"Stowasser, M., Eisenhofer, G., Pamporaki, C., Yang, J. & Young, W. Jr. Confirmatory testing for primary aldosteronism: setting the record straight under new guidelines. Hypertension 83, e26302 (2026).","journal-title":"Hypertension"},{"key":"714_CR189","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1161\/HYPERTENSIONAHA.116.07214","volume":"68","author":"E Cornu","year":"2016","unstructured":"Cornu, E. et al. Suppression of aldosterone secretion after recumbent saline infusion does not exclude lateralized primary aldosteronism. Hypertension 68, 989\u2013994 (2016).","journal-title":"Hypertension"},{"key":"714_CR190","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1093\/ejendo\/lvaf170","volume":"193","author":"CH Tsai","year":"2025","unstructured":"Tsai, C. H. et al. Discordance and shortcomings of aldosterone suppression tests in primary aldosteronism. Eur. J. Endocrinol. 193, 348\u2013358 (2025). This recent study highlighted the discordance and suboptimal performance of various aldosterone suppression tests in PA diagnosis, supporting their non-essential role in recent guidelines for patients with clearly abnormal baseline values already diagnostic of PA.","journal-title":"Eur. J. Endocrinol."},{"key":"714_CR191","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.125.26008","volume":"83","author":"AA Leung","year":"2026","unstructured":"Leung, A. A. et al. Seated saline suppression test for lateralizing primary aldosteronism. Hypertension 83, e26008 (2026).","journal-title":"Hypertension"},{"key":"714_CR192","doi-asserted-by":"publisher","first-page":"bvae209","DOI":"10.1210\/jendso\/bvae209","volume":"9","author":"L Duquet","year":"2025","unstructured":"Duquet, L. et al. Oral sodium loading test is more sensitive than seated saline infusion test to confirm overt primary aldosteronism. J. Endocr. Soc. 9, bvae209 (2025).","journal-title":"J. Endocr. Soc."},{"key":"714_CR193","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1210\/jc.2011-2504","volume":"97","author":"K Nanba","year":"2012","unstructured":"Nanba, K. et al. Confirmatory testing in primary aldosteronism. J. Clin. Endocrinol. Metab. 97, 1688\u20131694 (2012).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"714_CR194","doi-asserted-by":"publisher","first-page":"bvad147","DOI":"10.1210\/jendso\/bvad147","volume":"8","author":"TC Freitas","year":"2023","unstructured":"Freitas, T. C. et al. Efficacy of oral furosemide test for primary aldosteronism diagnosis. J. Endocr. Soc. 8, bvad147 (2023).","journal-title":"J. Endocr. Soc."},{"key":"714_CR195","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1507\/endocrj.EJ11-0133","volume":"58","author":"T Nishikawa","year":"2011","unstructured":"Nishikawa, T. et al. Guidelines for the diagnosis and treatment of primary aldosteronism \u2014 the Japan Endocrine Society 2009. Endocr. J. 58, 711\u2013721 (2011).","journal-title":"Endocr. J."},{"key":"714_CR196","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1055\/a-2106-4663","volume":"131","author":"N Younes","year":"2023","unstructured":"Younes, N., Larose, S., Bourdeau, I., Therasse, E. & Lacroix, A. Role of adrenal vein sampling in guiding surgical decision in primary aldosteronism. Exp. Clin. Endocrinol. Diabetes 131, 418\u2013434 (2023).","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"714_CR197","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/cen.15139","volume":"102","author":"J Yang","year":"2025","unstructured":"Yang, J. et al. Adrenal vein sampling for primary aldosteronism: recommendations from the Australian and New Zealand Working Group. Clin. Endocrinol. 102, 31\u201343 (2025).","journal-title":"Clin. Endocrinol."},{"key":"714_CR198","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1210\/endrev\/bnaf007","volume":"46","author":"GP Rossi","year":"2025","unstructured":"Rossi, G. P., Battistel, M., Seccia, T. M., Rossi, F. B. & Rossitto, G. Subtyping of primary aldosteronism by adrenal venous sampling. Endocr. Rev. 46, 501\u2013517 (2025).","journal-title":"Endocr. Rev."},{"key":"714_CR199","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/S2213-8587(14)70069-5","volume":"3","author":"S Monticone","year":"2015","unstructured":"Monticone, S. et al. Adrenal vein sampling in primary aldosteronism: towards a standardised protocol. Lancet Diabetes Endocrinol. 3, 296\u2013303 (2015).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"714_CR200","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/S2213-8587(21)00210-2","volume":"9","author":"M Reincke","year":"2021","unstructured":"Reincke, M. et al. Diagnosis and treatment of primary aldosteronism. Lancet Diabetes Endocrinol. 9, 876\u2013892 (2021).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"714_CR201","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1210\/jc.2015-3915","volume":"101","author":"N El Ghorayeb","year":"2016","unstructured":"El Ghorayeb, N. et al. Basal and post-ACTH aldosterone and its ratios are useful during adrenal vein sampling in primary aldosteronism. J. Clin. Endocrinol. Metab. 101, 1826\u20131835 (2016).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"714_CR202","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1530\/EJE-20-0254","volume":"183","author":"MJ Desrochers","year":"2020","unstructured":"Desrochers, M. J. et al. Basal contralateral aldosterone suppression is rare in lateralized primary aldosteronism. Eur. J. Endocrinol. 183, 399\u2013409 (2020).","journal-title":"Eur. J. Endocrinol."},{"key":"714_CR203","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1161\/HYPERTENSIONAHA.121.17248","volume":"78","author":"N Yozamp","year":"2021","unstructured":"Yozamp, N. et al. Adrenocorticotropic hormone-stimulated adrenal venous sampling underestimates surgically curable primary aldosteronism: a retrospective cohort study and review of contemporary studies. Hypertension 78, 94\u2013103 (2021). This study and review of 11 other studies identified that ACTH bolus can decrease the lateralization index with discordance between the pre-ACTH and post-ACTH classifications of lateralization in up to 26% of cases and can underestimate surgically remediable PA; both basal and post-ACTH values should be considered for surgical indications during AVS.","journal-title":"Hypertension"},{"key":"714_CR204","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.38209","volume":"6","author":"S Yang","year":"2023","unstructured":"Yang, S. et al. Corticotropin stimulation in adrenal venous sampling for patients with primary aldosteronism: the ADOPA randomized clinical trial. JAMA Netw. Open 6, e2338209 (2023).","journal-title":"JAMA Netw. Open"},{"key":"714_CR205","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S2213-8587(16)30100-0","volume":"4","author":"T Dekkers","year":"2016","unstructured":"Dekkers, T. et al. Adrenal vein sampling versus CT scan to determine treatment in primary aldosteronism: an outcome-based randomised diagnostic trial. Lancet Diabetes Endocrinol. 4, 739\u2013746 (2016). First prospective, blinded RCT of AVS (performed only under ACTH perfusion) versus CT of abdomen to select patients for adrenalectomy in PA; both strategies showed similar final blood pressure outcomes. However, several caveats were highlighted in this study, and further studies identified better surgical outcomes when surgery was based on lateralized AVS.","journal-title":"Lancet Diabetes Endocrinol."},{"key":"714_CR206","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1161\/HYPERTENSIONAHA.118.11086","volume":"72","author":"K Omata","year":"2018","unstructured":"Omata, K. et al. Cellular and genetic causes of idiopathic hyperaldosteronism. Hypertension 72, 874\u2013880 (2018).","journal-title":"Hypertension"},{"key":"714_CR207","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1530\/EJE-21-0338","volume":"185","author":"I Hacini","year":"2021","unstructured":"Hacini, I. et al. Somatic mutations in adrenals from patients with primary aldosteronism not cured after adrenalectomy suggest common pathogenic mechanisms between unilateral and bilateral disease. Eur. J. Endocrinol. 185, 405\u2013412 (2021).","journal-title":"Eur. J. Endocrinol."},{"key":"714_CR208","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1210\/clinem\/dgac408","volume":"107","author":"K Nanba","year":"2022","unstructured":"Nanba, K. et al. Histopathology and genetic causes of primary aldosteronism in young adults. J. Clin. Endocrinol. Metab. 107, 2473\u20132482 (2022).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"714_CR209","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1161\/HYPERTENSIONAHA.123.21910","volume":"81","author":"AF Turcu","year":"2024","unstructured":"Turcu, A. F. et al. Multifocal, asymmetric bilateral primary aldosteronism cannot be excluded by strong adrenal vein sampling lateralization: an international retrospective cohort study. Hypertension 81, 604\u2013613 (2024). In patients who were not improved by unilateral adrenalectomy, multifocal, asymmetrical bilateral PA was relatively common and was not excluded despite robust AVS lateralization. Careful immunohistochemistry for CYP11B2 can identify such patients at risk for persistent PA.","journal-title":"Hypertension"},{"key":"714_CR210","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1161\/HYPERTENSIONAHA.125.24999","volume":"82","author":"P Vibhatavata","year":"2025","unstructured":"Vibhatavata, P. et al. Cosyntropin-stimulated aldosterone reserve of the nondominant adrenal predicts surgical outcomes in primary aldosteronism. Hypertension 82, 1687\u20131695 (2025).","journal-title":"Hypertension"},{"key":"714_CR211","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1177\/1457496918822622","volume":"109","author":"C Volpe","year":"2020","unstructured":"Volpe, C., Hamberger, B., Zedenius, J. & Juhlin, C. C. Impact of immunohistochemistry on the diagnosis and management of primary aldosteronism: an important tool for improved patient follow-up. Scand. J. Surg. 109, 133\u2013142 (2020).","journal-title":"Scand. J. Surg."},{"key":"714_CR212","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1161\/HYPERTENSIONAHA.121.17348","volume":"78","author":"LS Meyer","year":"2021","unstructured":"Meyer, L. S. et al. Single-center prospective cohort study on the histopathology, genotype, and postsurgical outcomes of patients with primary aldosteronism. Hypertension 78, 738\u2013746 (2021).","journal-title":"Hypertension"},{"key":"714_CR213","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.2967\/jnumed.109.064873","volume":"50","author":"RF Yen","year":"2009","unstructured":"Yen, R. F. et al. 131I-6\u03b2-iodomethyl-19-norcholesterol SPECT\/CT for primary aldosteronism patients with inconclusive adrenal venous sampling and CT results. J. Nucl. Med. 50, 1631\u20131637 (2009).","journal-title":"J. Nucl. Med."},{"key":"714_CR214","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/S1095-0397(99)00099-0","volume":"2","author":"M Bergstrom","year":"1999","unstructured":"Bergstrom, M. et al. PET with [11C]-metomidate for the visualization of adrenocortical tumors and discrimination from other lesions. Clin. Positron Imaging 2, 339 (1999).","journal-title":"Clin. Positron Imaging"},{"key":"714_CR215","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1210\/jc.2011-1537","volume":"97","author":"TJ Burton","year":"2012","unstructured":"Burton, T. J. et al. Evaluation of the sensitivity and specificity of 11C-metomidate positron emission tomography (PET)-CT for lateralizing aldosterone secretion by Conn\u2019s adenomas. J. Clin. Endocrinol. Metab. 97, 100\u2013109 (2012).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"714_CR216","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1530\/EJE-20-0532","volume":"183","author":"M Soinio","year":"2020","unstructured":"Soinio, M. et al. Functional imaging with 11C-metomidate PET for subtype diagnosis in primary aldosteronism. Eur. J. Endocrinol. 183, 539\u2013550 (2020).","journal-title":"Eur. J. Endocrinol."},{"key":"714_CR217","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/s41591-022-02114-5","volume":"29","author":"X Wu","year":"2023","unstructured":"Wu, X. et al. [11C]metomidate PET-CT versus adrenal vein sampling for diagnosing surgically curable primary aldosteronism: a prospective, within-patient trial. Nat. Med. 29, 190\u2013202 (2023). Prospective non-inferiority clinical trial of surgical PA selection by either metomidate imaging or AVS; both modalities yielded equivalent proportions chosen for surgery and overall accuracy in predicting unilateral disease despite modest individual inter-modality disagreement.","journal-title":"Nat. Med."},{"key":"714_CR218","doi-asserted-by":"publisher","first-page":"434","DOI":"10.2967\/jnumed.124.268425","volume":"66","author":"D Gillett","year":"2025","unstructured":"Gillett, D. et al. A phase I\/IIa clinical trial to evaluate safety and adrenal uptake of para-chloro-2-[18F]fluoroethyletomidate in healthy volunteers and patients with primary aldosteronism. J. Nucl. Med. 66, 434\u2013440 (2025).","journal-title":"J. Nucl. Med."},{"key":"714_CR219","doi-asserted-by":"publisher","first-page":"336","DOI":"10.7326\/ANNALS-24-00761","volume":"178","author":"E Goodchild","year":"2025","unstructured":"Goodchild, E. et al. Molecular imaging versus adrenal vein sampling for the detection of surgically curable primary aldosteronism: a prospective within-patient trial. Ann. Intern. Med. 178, 336\u2013347 (2025).","journal-title":"Ann. Intern. Med."},{"key":"714_CR220","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1161\/HYPERTENSIONAHA.117.09975","volume":"71","author":"B Heinze","year":"2018","unstructured":"Heinze, B. et al. Targeting CXCR4 (CXC chemokine receptor type 4) for molecular imaging of aldosterone-producing adenoma. Hypertension 71, 317\u2013325 (2018).","journal-title":"Hypertension"},{"key":"714_CR221","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.55609","volume":"6","author":"J Hu","year":"2023","unstructured":"Hu, J. et al. Accuracy of gallium-68 pentixafor positron emission tomography-computed tomography for subtyping diagnosis of primary aldosteronism. JAMA Netw. Open 6, e2255609 (2023).","journal-title":"JAMA Netw. Open"},{"key":"714_CR222","doi-asserted-by":"publisher","first-page":"9321","DOI":"10.1021\/acs.jmedchem.1c00539","volume":"64","author":"K Sander","year":"2021","unstructured":"Sander, K. et al. Development of [18F]AldoView as the first highly selective aldosterone synthase PET tracer for imaging of primary hyperaldosteronism. J. Med. Chem. 64, 9321\u20139329 (2021).","journal-title":"J. Med. Chem."},{"key":"714_CR223","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1097\/RLU.0000000000006014","volume":"50","author":"T Long","year":"2025","unstructured":"Long, T. et al. First-in-human evaluation of [18F]AldoView: a highly selective PET tracer for aldosterone synthase imaging in primary aldosteronism. Clin. Nucl. Med. 50, 847\u2013855 (2025).","journal-title":"Clin. Nucl. Med."},{"key":"714_CR224","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1056\/NEJMc2507481","volume":"393","author":"E \u00c5rstad","year":"2025","unstructured":"\u00c5rstad, E. et al. Adrenal aldosterone synthase expression imaging in primary aldosteronism. N. Engl. J. Med. 393, 2168\u20132170 (2025). A pilot PET\u2013CT study using a newly developed CYP11B2-specific 18F radioligand showed selective imaging of macroscopic and microscopic aldosterone-producing adrenal lesions in 17 patients with PA.","journal-title":"N. Engl. J. Med."},{"key":"714_CR225","doi-asserted-by":"publisher","first-page":"R51","DOI":"10.1093\/ejendo\/lvaf218","volume":"193","author":"TA Williams","year":"2025","unstructured":"Williams, T. A., Constantinescu, G. & Pamporaki, C. Biomarkers for subtype stratification in primary aldosteronism: current and future perspectives. Eur. J. Endocrinol. 193, R51\u2013R64 (2025).","journal-title":"Eur. J. Endocrinol."},{"key":"714_CR226","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.mce.2015.04.022","volume":"411","author":"S Monticone","year":"2015","unstructured":"Monticone, S. et al. Immunohistochemical, genetic and clinical characterization of sporadic aldosterone-producing adenomas. Mol. Cell. Endocrinol. 411, 146\u2013154 (2015).","journal-title":"Mol. Cell. Endocrinol."},{"key":"714_CR227","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1161\/HYPERTENSIONAHA.114.04453","volume":"65","author":"F Satoh","year":"2015","unstructured":"Satoh, F. et al. Measurement of peripheral plasma 18-oxocortisol can discriminate unilateral adenoma from bilateral diseases in patients with primary aldosteronism. Hypertension 65, 1096\u20131102 (2015).","journal-title":"Hypertension"},{"key":"714_CR228","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.16209","volume":"3","author":"G Eisenhofer","year":"2020","unstructured":"Eisenhofer, G. et al. Use of steroid profiling combined with machine learning for identification and subtype classification in primary aldosteronism. JAMA Netw. Open 3, e2016209 (2020).","journal-title":"JAMA Netw. Open"},{"key":"714_CR229","doi-asserted-by":"publisher","first-page":"106445","DOI":"10.1016\/j.jsbmb.2023.106445","volume":"237","author":"A Prete","year":"2024","unstructured":"Prete, A. et al. Urine steroid metabolomics as a diagnostic tool in primary aldosteronism. J. Steroid Biochem. Mol. Biol. 237, 106445 (2024).","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"714_CR230","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1161\/HYPERTENSIONAHA.124.23418","volume":"81","author":"B Vekony","year":"2024","unstructured":"Vekony, B. et al. Circulating miRNAs and machine learning for lateralizing primary aldosteronism. Hypertension 81, 2479\u20132488 (2024).","journal-title":"Hypertension"},{"key":"714_CR231","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1161\/HYPERTENSIONAHA.122.17964","volume":"79","author":"F Buffolo","year":"2022","unstructured":"Buffolo, F., Tetti, M., Mulatero, P. & Monticone, S. Aldosterone as a mediator of cardiovascular damage. Hypertension 79, 1899\u20131911 (2022).","journal-title":"Hypertension"},{"key":"714_CR232","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/jhh.2010.102","volume":"25","author":"E Pimenta","year":"2011","unstructured":"Pimenta, E. et al. Unilateral adrenalectomy improves urinary protein excretion but does not abolish its relationship to sodium excretion in patients with aldosterone-producing adenoma. J. Hum. Hypertens. 25, 592\u2013599 (2011).","journal-title":"J. Hum. Hypertens."},{"key":"714_CR233","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1152\/ajplegacy.1965.208.6.1281","volume":"208","author":"G Wolf","year":"1965","unstructured":"Wolf, G. Effect of deoxycorticosterone on sodium appetite of intact and adrenalectomized rats. Am. J. Physiol. 208, 1281\u20131285 (1965).","journal-title":"Am. J. Physiol."},{"key":"714_CR234","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1046\/j.1523-1755.2000.00972.x","volume":"57","author":"RR Sakai","year":"2000","unstructured":"Sakai, R. R., McEwen, B. S., Fluharty, S. J. & Ma, L. Y. The amygdala: site of genomic and nongenomic arousal of aldosterone-induced sodium intake. Kidney Int. 57, 1337\u20131345 (2000).","journal-title":"Kidney Int."},{"key":"714_CR235","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1523\/JNEUROSCI.3115-05.2006","volume":"26","author":"JC Geerling","year":"2006","unstructured":"Geerling, J. C., Engeland, W. C., Kawata, M. & Loewy, A. D. Aldosterone target neurons in the nucleus tractus solitarius drive sodium appetite. J. Neurosci. 26, 411\u2013417 (2006).","journal-title":"J. Neurosci."},{"key":"714_CR236","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1161\/HYPERTENSIONAHA.120.16440","volume":"77","author":"C Adolf","year":"2021","unstructured":"Adolf, C. et al. Altered taste perception for sodium chloride in patients with primary aldosteronism: a prospective cohort study. Hypertension 77, 1332\u20131340 (2021).","journal-title":"Hypertension"},{"key":"714_CR237","doi-asserted-by":"publisher","first-page":"3989","DOI":"10.1210\/jc.2016-1963","volume":"101","author":"R Baudrand","year":"2016","unstructured":"Baudrand, R., Guarda, F. J., Torrey, J., Williams, G. & Vaidya, A. Dietary sodium restriction increases the risk of misinterpreting mild cases of primary aldosteronism. J. Clin. Endocrinol. Metab. 101, 3989\u20133996 (2016).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"714_CR238","doi-asserted-by":"publisher","first-page":"1124479","DOI":"10.3389\/fendo.2023.1124479","volume":"14","author":"L Zhou","year":"2023","unstructured":"Zhou, L. et al. Effects of a low-sodium diet in patients with idiopathic hyperaldosteronism: a randomized controlled trial. Front. Endocrinol. 14, 1124479 (2023).","journal-title":"Front. Endocrinol."},{"key":"714_CR239","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/bjs.9744","volume":"102","author":"A Muth","year":"2015","unstructured":"Muth, A., Ragnarsson, O., Johannsson, G. & W\u00e4ngberg, B. Systematic review of surgery and outcomes in patients with primary aldosteronism. Br. J. Surg. 102, 307\u2013317 (2015).","journal-title":"Br. J. Surg."},{"key":"714_CR240","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1111\/jch.12916","volume":"18","author":"JL Benham","year":"2016","unstructured":"Benham, J. L. et al. Proportion of patients with hypertension resolution following adrenalectomy for primary aldosteronism: a systematic review and meta-analysis. J. Clin. Hypertens. 18, 1205\u20131212 (2016).","journal-title":"J. Clin. Hypertens."},{"key":"714_CR241","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/S2213-8587(17)30135-3","volume":"5","author":"TA Williams","year":"2017","unstructured":"Williams, T. A. et al. Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol. 5, 689\u2013699 (2017). This study standardized outcome definitions after adrenalectomy for unilateral PA and provides real-world remission data that guide patient counselling, surgical decision-making and evaluation of treatment success.","journal-title":"Lancet Diabetes Endocrinol."},{"key":"714_CR242","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1097\/SLA.0b013e318165c075","volume":"247","author":"R Zarnegar","year":"2008","unstructured":"Zarnegar, R. et al. The aldosteronoma resolution score: predicting complete resolution of hypertension after adrenalectomy for aldosteronoma. Ann. Surg. 247, 511\u2013518 (2008).","journal-title":"Ann. Surg."},{"key":"714_CR243","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1007\/s00268-019-05074-z","volume":"43","author":"W Vorselaars","year":"2019","unstructured":"Vorselaars, W. et al. Validation of the aldosteronoma resolution score within current clinical practice. World J. Surg. 43, 2459\u20132468 (2019).","journal-title":"World J. Surg."},{"key":"714_CR244","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1097\/SLA.0000000000003200","volume":"272","author":"J Burrello","year":"2020","unstructured":"Burrello, J. et al. The primary aldosteronism surgical outcome score for the prediction of clinical outcomes after adrenalectomy for unilateral primary aldosteronism. Ann. Surg. 272, 1125\u20131132 (2020).","journal-title":"Ann. Surg."},{"key":"714_CR245","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1530\/EJE-21-0836","volume":"186","author":"V-C Wu","year":"2021","unstructured":"Wu, V.-C. et al. Long-term mortality and cardiovascular events in patients with unilateral primary aldosteronism after targeted treatments. Eur. J. Endocrinol. 186, 195\u2013205 (2021). This long-term cohort study demonstrated that patients with unilateral PA treated with either adrenalectomy or mineralocorticoid receptor antagonists had superior survival and reduced cardiovascular event rates compared with those with essential hypertension.","journal-title":"Eur. J. Endocrinol."},{"key":"714_CR246","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1093\/ejendo\/lvaf118","volume":"192","author":"TS Goldbaum","year":"2025","unstructured":"Goldbaum, T. S. et al. Histopathological evaluation based on CYP11B2 staining predicts outcomes in unilateral primary aldosteronism. Eur. J. Endocrinol. 192, 763\u2013775 (2025).","journal-title":"Eur. J. Endocrinol."},{"key":"714_CR247","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1161\/HYPERTENSIONAHA.123.22281","volume":"81","author":"M Tetti","year":"2024","unstructured":"Tetti, M. et al. Unilateral primary aldosteronism: long-term disease recurrence after adrenalectomy. Hypertension 81, 936\u2013945 (2024).","journal-title":"Hypertension"},{"key":"714_CR248","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1097\/01.ju.0000162045.68387.c3","volume":"174","author":"S Ishidoya","year":"2005","unstructured":"Ishidoya, S. et al. Laparoscopic partial versus total adrenalectomy for aldosterone producing adenoma. J. Urol. 174, 40\u201343 (2005).","journal-title":"J. Urol."},{"key":"714_CR249","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1016\/j.juro.2010.12.051","volume":"185","author":"B Fu","year":"2011","unstructured":"Fu, B. et al. Long-term results of a prospective, randomized trial comparing retroperitoneoscopic partial versus total adrenalectomy for aldosterone producing adenoma. J. Urol. 185, 1578\u20131582 (2011).","journal-title":"J. Urol."},{"key":"714_CR250","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1016\/j.euf.2020.06.023","volume":"7","author":"U Anceschi","year":"2021","unstructured":"Anceschi, U. et al. Minimally invasive partial versus total adrenalectomy for the treatment of primary aldosteronism: results of a multicenter series according to the PASO criteria. Eur. Urol. Focus\u00a07, 1418\u20131423 (2021).","journal-title":"Eur. Urol. Focus"},{"key":"714_CR251","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1161\/HYPERTENSIONAHA.121.18006","volume":"78","author":"V-C Wu","year":"2021","unstructured":"Wu, V.-C. et al. Subtypes of histopathologically classical aldosterone-producing adenomas yield various transcriptomic signaling and outcomes. Hypertension 78, 1791\u20131800 (2021). This study revealed that, even among histopathologically classical APAs, distinct transcriptomic subtypes exist, which correlate with different signalling pathways and lead to variable post-adrenalectomy outcomes.","journal-title":"Hypertension"},{"key":"714_CR252","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11051263","volume":"11","author":"RS Flammia","year":"2022","unstructured":"Flammia, R. S. Minimally invasive partial vs. total adrenalectomy for the treatment of unilateral primary aldosteronism: a systematic review and meta-analysis. J. Clin. Med. 11, 1263 (2022).","journal-title":"J. Clin. Med."},{"key":"714_CR253","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1002\/bjs.10219","volume":"103","author":"SY Liu","year":"2016","unstructured":"Liu, S. Y. et al. Radiofrequency ablation compared with laparoscopic adrenalectomy for aldosterone-producing adenoma. Br. J. Surg. 103, 1476\u20131486 (2016).","journal-title":"Br. J. Surg."},{"key":"714_CR254","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1111\/jch.13960","volume":"22","author":"H Zhang","year":"2020","unstructured":"Zhang, H. et al. Adrenal artery ablation for primary aldosteronism without apparent aldosteronoma: an efficacy and safety, proof-of-principle trial. J. Clin. Hypertens. 22, 1618\u20131626 (2020).","journal-title":"J. Clin. Hypertens."},{"key":"714_CR255","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.jvir.2016.03.042","volume":"27","author":"A Sarwar","year":"2016","unstructured":"Sarwar, A. et al. Clinical outcomes following percutaneous radiofrequency ablation of unilateral aldosterone-producing adenoma: comparison with adrenalectomy. J. Vasc. Interv. Radiol. 27, 961\u2013967 (2016).","journal-title":"J. Vasc. Interv. Radiol."},{"key":"714_CR256","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s12020-025-04218-7","volume":"89","author":"A Nadeem","year":"2025","unstructured":"Nadeem, A. et al. Radiofrequency ablation versus laparoscopic adrenalectomy for aldosterone-producing adenomas: a systematic review and meta-analysis. Endocrine 89, 39\u201351 (2025).","journal-title":"Endocrine"},{"key":"714_CR257","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S0140-6736(24)02755-7","volume":"405","author":"G Argentesi","year":"2025","unstructured":"Argentesi, G. et al. Endoscopic, ultrasound-guided, radiofrequency ablation of aldosterone-producing adenomas (FABULAS): a UK, multicentre, prospective, proof-of-concept trial. Lancet 405, 637\u2013647 (2025).","journal-title":"Lancet"},{"key":"714_CR258","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1530\/EJE-22-0286","volume":"187","author":"W-C Wu","year":"2022","unstructured":"Wu, W.-C. et al. Cortisol-producing adenoma-related somatic mutations in unilateral primary aldosteronism with concurrent autonomous cortisol secretion: their prevalence and clinical characteristics. Eur. J. Endocrinol. 187, 519\u2013530 (2022). This study investigated the co-occurrence of autonomous cortisol secretion and PA, reporting that unilateral PA with concurrent autonomous cortisol secretion is associated with ACTH-independent cortisol-related somatic mutations (for example, in PRKACA and CTNNB1) and specific clinical features.","journal-title":"Eur. J. Endocrinol."},{"key":"714_CR259","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1093\/ejendo\/lvaf019","volume":"192","author":"M Grundy","year":"2025","unstructured":"Grundy, M. et al. Discordance between adrenal vein sampling and imaging: the role of unilateral cortisol excess. Eur. J. Endocrinol. 192, 191\u2013201 (2025).","journal-title":"Eur. J. Endocrinol."},{"key":"714_CR260","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/S2213-8587(25)00062-2","volume":"13","author":"A Tabarin","year":"2025","unstructured":"Tabarin, A. et al. Surgery for the treatment of arterial hypertension in patients with unilateral adrenal incidentalomas and mild autonomous cortisol secretion (CHIRACIC): a multicentre, open-label, superiority randomised controlled trial. Lancet Diabetes Endocrinol. 13, 580\u2013590 (2025).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"714_CR261","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/jhh.2012.27","volume":"27","author":"E Pimenta","year":"2013","unstructured":"Pimenta, E., Gordon, R. D. & Stowasser, M. Salt, aldosterone and hypertension. J. Hum. Hypertens. 27, 1\u20136 (2013).","journal-title":"J. Hum. Hypertens."},{"key":"714_CR262","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1055\/a-2172-7228","volume":"56","author":"L Chen","year":"2024","unstructured":"Chen, L., Adolf, C., Reincke, M. & Schneider, H. Salt and aldosterone \u2014 reciprocal and combined effects in preclinical models and humans. Hormone Metab. Res. 56, 99\u2013106 (2024).","journal-title":"Hormone Metab. Res."},{"key":"714_CR263","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/joim.13618","volume":"294","author":"H Schneider","year":"2023","unstructured":"Schneider, H. et al. Moderate dietary salt restriction improves blood pressure and mental well-being in patients with primary aldosteronism: the salt CONNtrol trial. J. Intern. Med. 294, 47\u201357 (2023).","journal-title":"J. Intern. Med."},{"key":"714_CR264","doi-asserted-by":"publisher","first-page":"1428054","DOI":"10.3389\/fimmu.2024.1428054","volume":"15","author":"HF Nowotny","year":"2024","unstructured":"Nowotny, H. F. et al. Sex-dependent modulation of T and NK cells and gut microbiome by low sodium diet in patients with primary aldosteronism. Front. Immunol. 15, 1428054 (2024).","journal-title":"Front. Immunol."},{"key":"714_CR265","doi-asserted-by":"publisher","first-page":"204062232412397","DOI":"10.1177\/20406223241239775","volume":"15","author":"WY Ho","year":"2024","unstructured":"Ho, W. Y. et al. Comparison of different medical treatments for primary hyperaldosteronism: a systematic review and network meta-analysis. Ther. Adv. Chronic Dis. 15, 20406223241239775 (2024).","journal-title":"Ther. Adv. Chronic Dis."},{"key":"714_CR266","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1097\/HJH.0b013e3283455ca5","volume":"29","author":"HK Parthasarathy","year":"2011","unstructured":"Parthasarathy, H. K. et al. A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J. Hypertens. 29, 980\u2013990 (2011).","journal-title":"J. Hypertens."},{"key":"714_CR267","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1161\/CIRCULATIONAHA.124.071452","volume":"151","author":"J Hu","year":"2025","unstructured":"Hu, J. et al. Efficacy and safety of finerenone in patients with primary aldosteronism: a pilot randomized controlled trial. Circulation 151, 196\u2013198 (2025).","journal-title":"Circulation"},{"key":"714_CR268","doi-asserted-by":"publisher","first-page":"K50","DOI":"10.1093\/ejendo\/lvaf099","volume":"192","author":"T Uslar","year":"2025","unstructured":"Uslar, T., Sanfuentes, B., Mu\u00f1oz, I., Vaidya, A. & Baudrand, R. Real-world outcomes of finerenone in primary aldosteronism. Eur. J. Endocrinol. 192, K50\u2013K53 (2025).","journal-title":"Eur. J. Endocrinol."},{"key":"714_CR269","doi-asserted-by":"publisher","first-page":"103369","DOI":"10.1016\/j.dsx.2025.103369","volume":"20","author":"S Li","year":"2026","unstructured":"Li, S. et al. Efficacy and safety of finerenone in the treatment of primary aldosteronism: a prospective clinical study. Diabetes Metab. Syndr. 20, 103369 (2026).","journal-title":"Diabetes Metab. Syndr."},{"key":"714_CR270","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.125.26048","volume":"83","author":"P Li","year":"2026","unstructured":"Li, P. et al. Efficacy and safety of finerenone in patients with primary aldosteronism: a multicenter prospective study. Hypertension 83, e26048 (2026).","journal-title":"Hypertension"},{"key":"714_CR271","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","volume":"43","author":"R Agarwal","year":"2022","unstructured":"Agarwal, R. et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur. Heart J. 43, 474\u2013484 (2022).","journal-title":"Eur. Heart J."},{"key":"714_CR272","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/s41440-020-00570-5","volume":"44","author":"F Satoh","year":"2021","unstructured":"Satoh, F. et al. Efficacy and safety of esaxerenone (CS-3150), a newly available nonsteroidal mineralocorticoid receptor blocker, in hypertensive patients with primary aldosteronism. Hypertens. Res. 44, 464\u2013472 (2021).","journal-title":"Hypertens. Res."},{"key":"714_CR273","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41440-023-01412-w","volume":"47","author":"Y Yoshida","year":"2024","unstructured":"Yoshida, Y. et al. Effects of esaxerenone on blood pressure, urinary albumin excretion, serum levels of NT-proBNP, and quality of life in patients with primary aldosteronism. Hypertens. Res. 47, 157\u2013167 (2024).","journal-title":"Hypertens. Res."},{"key":"714_CR274","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/clpt.1982.9","volume":"31","author":"GT Griffing","year":"1982","unstructured":"Griffing, G. T. et al. Amiloride in primary hyperaldosteronism. Clin. Pharmacol. Ther. 31, 56\u201361 (1982).","journal-title":"Clin. Pharmacol. Ther."},{"key":"714_CR275","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/clpt.1980.42","volume":"27","author":"WH Hoefnagels","year":"1980","unstructured":"Hoefnagels, W. H., Drayer, J. I., Smals, A. G. & Kloppenborg, P. W. Spironolactone and amiloride in hypertensive patients with and without aldosterone excess. Clin. Pharmacol. Ther. 27, 317\u2013323 (1980).","journal-title":"Clin. Pharmacol. Ther."},{"key":"714_CR276","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1161\/HYPERTENSIONAHA.118.11339","volume":"72","author":"G Jia","year":"2018","unstructured":"Jia, G. et al. Epithelial sodium channel in aldosterone-induced endothelium stiffness and aortic dysfunction. Hypertension 72, 731\u2013738 (2018).","journal-title":"Hypertension"},{"key":"714_CR277","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1146\/annurev-physiol-022724-105050","volume":"87","author":"A Kirabo","year":"2025","unstructured":"Kirabo, A., Masenga, S. K. & Kleyman, T. R. Epithelial Na+ channels, immune cells, and salt. Annu. Rev. Physiol. 87, 381\u2013395 (2025).","journal-title":"Annu. Rev. Physiol."},{"key":"714_CR278","doi-asserted-by":"publisher","first-page":"102576","DOI":"10.1016\/j.eclinm.2024.102576","volume":"71","author":"P Mulatero","year":"2024","unstructured":"Mulatero, P. et al. Safety and efficacy of once-daily dexfadrostat phosphate in patients with primary aldosteronism: a randomised, parallel group, multicentre, phase 2 trial. eClinicalMedicine 71, 102576 (2024).","journal-title":"eClinicalMedicine"},{"key":"714_CR279","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1056\/NEJMc2508629","volume":"393","author":"AF Turcu","year":"2025","unstructured":"Turcu, A. F. et al. Phase 2a study of baxdrostat in primary aldosteronism. N. Engl. J. Med. 393, 515\u2013518 (2025).","journal-title":"N. Engl. J. Med."},{"key":"714_CR280","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1056\/NEJMoa2213169","volume":"388","author":"MW Freeman","year":"2023","unstructured":"Freeman, M. W. et al. Phase 2 trial of baxdrostat for treatment-resistant hypertension. N. Engl. J. Med. 388, 395\u2013405 (2023).","journal-title":"N. Engl. J. Med."},{"key":"714_CR281","doi-asserted-by":"publisher","first-page":"e557","DOI":"10.1210\/clinem\/dgae823","volume":"110","author":"M Azizi","year":"2025","unstructured":"Azizi, M., Riancho, J. & Amar, L. Aldosterone synthase inhibitors: a revival for treatment of renal and cardiovascular diseases. J. Clin. Endocrinol. Metab. 110, e557\u2013e565 (2025).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"714_CR282","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT07007793 (2026)."},{"key":"714_CR283","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1056\/NEJMc2512144","volume":"393","author":"C Richa","year":"2025","unstructured":"Richa, C., Lacroix, A. & Young, J. Osilodrostat for bilateral adrenal hypercortisolism in primary aldosteronism. N. Engl. J. Med. 393, 2170\u20132172 (2025).","journal-title":"N. Engl. J. Med."},{"key":"714_CR284","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/S2213-8587(25)00263-3","volume":"13","author":"S Katsuragawa","year":"2025","unstructured":"Katsuragawa, S., Le, M. V., Fuller, P. J. & Yang, J. Post-treatment renin status and cardiovascular, renal, and mortality outcomes in medically treated primary aldosteronism: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 13, 1041\u20131053 (2025).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"714_CR285","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.124.038714","volume":"14","author":"CW Huang","year":"2025","unstructured":"Huang, C. W. et al. Major adverse cardiovascular events in primary aldosteronism after adrenalectomy or mineralocorticoid receptor antagonist treatment: a systematic review and meta-analysis. J. Am. Heart Assoc. 14, e038714 (2025). This systematic review and meta-analysis compared the occurrence of major adverse cardiovascular events after targeted treatment for PA, finding that adrenalectomy was associated with a lower risk of major adverse cardiovascular events compared with mineralocorticoid receptor antagonist therapy.","journal-title":"J. Am. Heart Assoc."},{"key":"714_CR286","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S2213-8587(24)00308-5","volume":"13","author":"J Yang","year":"2025","unstructured":"Yang, J. et al. Outcomes after medical treatment for primary aldosteronism: an international consensus and analysis of treatment response in an international cohort. Lancet Diabetes Endocrinol. 13, 119\u2013133 (2025). This study established a standardized framework for categorizing medical treatment outcomes in PA and provided a real-world snapshot of treatment response rates.","journal-title":"Lancet Diabetes Endocrinol."},{"key":"714_CR287","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1093\/ajh\/hpac079","volume":"35","author":"A Vaidya","year":"2022","unstructured":"Vaidya, A., Hundemer, G. L., Nanba, K., Parksook, W. W. & Brown, J. M. Primary aldosteronism: state-of-the-art review. Am. J. Hypertens. 35, 967\u2013988 (2022).","journal-title":"Am. J. Hypertens."},{"key":"714_CR288","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.nefro.2023.05.004","volume":"43","author":"A Ortiz","year":"2023","unstructured":"Ortiz, A. et al. Consensus document on the management of hyperkalemia. Nefrologia 43, 765\u2013782 (2023).","journal-title":"Nefrologia"},{"key":"714_CR289","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1210\/endrev\/bnad024","volume":"45","author":"GL Hundemer","year":"2024","unstructured":"Hundemer, G. L. et al. Biomarkers to guide medical therapy in primary aldosteronism. Endocr. Rev. 45, 69\u201394 (2024).","journal-title":"Endocr. Rev."},{"key":"714_CR290","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1055\/s-0043-121706","volume":"49","author":"MS Velema","year":"2017","unstructured":"Velema, M. S. et al. Health-related quality of life and mental health in primary aldosteronism: a systematic review. Hormone Metab. Res. 49, 943\u2013950 (2017).","journal-title":"Hormone Metab. Res."},{"key":"714_CR291","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13419","volume":"51","author":"F Buffolo","year":"2021","unstructured":"Buffolo, F. et al. Quality of life in primary aldosteronism: a prospective observational study. Eur. J. Clin. Invest. 51, e13419 (2021).","journal-title":"Eur. J. Clin. Invest."},{"key":"714_CR292","doi-asserted-by":"publisher","first-page":"4105","DOI":"10.1210\/en.2015-1390","volume":"156","author":"E Atucha","year":"2015","unstructured":"Atucha, E. et al. A mixed glucocorticoid\/mineralocorticoid selective modulator with dominant antagonism in the male rat brain. Endocrinology 156, 4105\u20134114 (2015).","journal-title":"Endocrinology"},{"key":"714_CR293","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.psyneuen.2018.09.010","volume":"105","author":"K Wingenfeld","year":"2019","unstructured":"Wingenfeld, K. & Otte, C. Mineralocorticoid receptor function and cognition in health and disease. Psychoneuroendocrinology 105, 25\u201335 (2019).","journal-title":"Psychoneuroendocrinology"},{"key":"714_CR294","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1046\/j.1523-1755.2000.00971.x","volume":"57","author":"ER de Kloet","year":"2000","unstructured":"de Kloet, E. R. et al. Brain mineralocorticoid receptors and centrally regulated functions. Kidney Int. 57, 1329\u20131336 (2000).","journal-title":"Kidney Int."},{"key":"714_CR295","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.1210\/jc.2011-0138","volume":"96","author":"AH Ahmed","year":"2011","unstructured":"Ahmed, A. H., Gordon, R. D., Sukor, N., Pimenta, E. & Stowasser, M. Quality of life in patients with bilateral primary aldosteronism before and during treatment with spironolactone and\/or amiloride, including a comparison with our previously published results in those with unilateral disease treated surgically. J. Clin. Endocrinol. Metab. 96, 2904\u20132911 (2011).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"714_CR296","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1210\/jc.2009-1763","volume":"95","author":"N Sukor","year":"2010","unstructured":"Sukor, N., Kogovsek, C., Gordon, R. D., Robson, D. & Stowasser, M. Improved quality of life, blood pressure, and biochemical status following laparoscopic adrenalectomy for unilateral primary aldosteronism. J. Clin. Endocrinol. Metab. 95, 1360\u20131364 (2010).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"714_CR297","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1210\/jc.2017-01442","volume":"103","author":"M Velema","year":"2018","unstructured":"Velema, M. et al. Quality of life in primary aldosteronism: a comparative effectiveness study of adrenalectomy and medical treatment. J. Clin. Endocrinol. Metab. 103, 16\u201324 (2018).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"714_CR298","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1530\/EC-21-0125","volume":"10","author":"YK Tan","year":"2021","unstructured":"Tan, Y. K. et al. Improvement in quality of life and psychological symptoms after treatment for primary aldosteronism: Asian cohort study. Endocr. Connect. 10, 834\u2013844 (2021).","journal-title":"Endocr. Connect."},{"key":"714_CR299","doi-asserted-by":"publisher","DOI":"10.1186\/s12893-018-0432-1","volume":"18","author":"M Citton","year":"2019","unstructured":"Citton, M., Viel, G., Torresan, F., Rossi, G. P. & Iacobone, M. Effect of unilateral adrenalectomy on the quality of life of patients with lateralized primary aldosteronism. BMC Surg. 18, 105 (2019).","journal-title":"BMC Surg."},{"key":"714_CR300","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.eprac.2023.10.003","volume":"30","author":"J Yu","year":"2024","unstructured":"Yu, J. et al. A prospective observational study of factors affecting the change in quality of life in patients with primary aldosteronism after treatment. Endocr. Pract. 30, 19\u201324 (2024).","journal-title":"Endocr. Pract."},{"key":"714_CR301","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1093\/ejendo\/lvaf052","volume":"192","author":"S Reel","year":"2025","unstructured":"Reel, S. et al. Identification of hypertension subtypes using microRNA profiles and machine learning. Eur. J. Endocrinol. 192, 418\u2013428 (2025).","journal-title":"Eur. J. Endocrinol."},{"key":"714_CR302","doi-asserted-by":"publisher","DOI":"10.1111\/eci.70081","volume":"55","author":"CH Tsai","year":"2025","unstructured":"Tsai, C. H. et al. Proteomic signatures to detect unilateral primary aldosteronism in hypertensive patients. Eur. J. Clin. Invest. 55, e70081 (2025).","journal-title":"Eur. J. Clin. Invest."},{"key":"714_CR303","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1210\/clinem\/dgaa954","volume":"106","author":"Z Erlic","year":"2021","unstructured":"Erlic, Z. et al. Targeted metabolomics as a tool in discriminating endocrine from primary hypertension. J. Clin. Endocrinol. Metab. 106, 1111\u20131128 (2021).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"714_CR304","doi-asserted-by":"publisher","first-page":"104276","DOI":"10.1016\/j.ebiom.2022.104276","volume":"84","author":"PS Reel","year":"2022","unstructured":"Reel, P. S. et al. Machine learning for classification of hypertension subtypes using multi-omics: a multi-centre, retrospective, data-driven study. eBioMedicine 84, 104276 (2022). This study has developed multi-omics biomarkers that can distinguish PA from primary hypertension with high sensitivity and specificity by integrating multidimensional omics analyses using innovative machine learning approaches.","journal-title":"eBioMedicine"},{"key":"714_CR305","doi-asserted-by":"publisher","DOI":"10.3390\/metabo12080755","volume":"12","author":"S Reel","year":"2022","unstructured":"Reel, S. et al. Predicting hypertension subtypes with machine learning using targeted metabolites and their ratios. Metabolites 12, 755 (2022).","journal-title":"Metabolites"},{"key":"714_CR306","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.1515\/cclm-2025-0200","volume":"63","author":"G Eisenhofer","year":"2025","unstructured":"Eisenhofer, G. et al. Robustness of steroidomics-based machine learning for diagnosis of primary aldosteronism: a laboratory medicine perspective. Clin. Chem. Lab. Med. 63, 2236\u20132246 (2025).","journal-title":"Clin. Chem. Lab. Med."},{"key":"714_CR307","doi-asserted-by":"publisher","first-page":"7281","DOI":"10.7150\/thno.100848","volume":"14","author":"L He","year":"2024","unstructured":"He, L. et al. [18F]AlF-NOTA-pentixather PET\/CT of CXCR4 in patients with suspected primary hyperaldosteronism. Theranostics 14, 7281\u20137291 (2024).","journal-title":"Theranostics"},{"key":"714_CR308","doi-asserted-by":"publisher","first-page":"312","DOI":"10.2967\/jnmt.125.270687","volume":"53","author":"D Gillett","year":"2025","unstructured":"Gillett, D. et al. Voxel-level comparison of [18F]CETO and [11C]MTO for molecular imaging of primary aldosteronism. J. Nucl. Med. Technol. 53, 312\u2013317 (2025).","journal-title":"J. Nucl. Med. Technol."},{"key":"714_CR309","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1210\/jc.2008-2803","volume":"94","author":"N Sukor","year":"2009","unstructured":"Sukor, N., Gordon, R. D., Ku, Y. K., Jones, M. & Stowasser, M. Role of unilateral adrenalectomy in bilateral primary aldosteronism: a 22-year single center experience. J. Clin. Endocrinol. Metab. 94, 2437\u20132445 (2009).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"714_CR310","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/S2213-8587(22)00253-4","volume":"10","author":"TA Williams","year":"2022","unstructured":"Williams, T. A. et al. Adrenal surgery for bilateral primary aldosteronism: an international retrospective cohort study. Lancet Diabetes Endocrinol. 10, 769\u2013771 (2022).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"714_CR311","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1172\/JCI91733","volume":"127","author":"UI Scholl","year":"2017","unstructured":"Scholl, U. I. et al. Macrolides selectively inhibit mutant KCNJ5 potassium channels that cause aldosterone-producing adenoma. J. Clin. Invest. 127, 2739\u20132750 (2017).","journal-title":"J. Clin. Invest."},{"key":"714_CR312","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-061671","volume":"12","author":"AK Nainani","year":"2022","unstructured":"Nainani, A. K., Yang, J., Peters, S. & Russell, G. \u2018I can\u2019t understand why others don\u2019t screen more\u2019: a qualitative study exploring why Australian general practitioners screen for primary aldosteronism. BMJ Open 12, e061671 (2022).","journal-title":"BMJ Open"},{"key":"714_CR313","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1093\/fampra\/cmae033","volume":"41","author":"K Tsan","year":"2024","unstructured":"Tsan, K., Yang, J., Nainani, A., Libianto, R. & Russell, G. Screening for primary aldosteronism in primary care: a scoping review. Fam. Pract. 41, 851\u2013856 (2024).","journal-title":"Fam. Pract."},{"key":"714_CR314","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1161\/HYPERTENSIONAHA.123.21965","volume":"81","author":"RA Ananda","year":"2024","unstructured":"Ananda, R. A. et al. Diagnostic delay and disease burden in primary aldosteronism: an international patient survey. Hypertension 81, 348\u2013360 (2024).","journal-title":"Hypertension"},{"key":"714_CR315","doi-asserted-by":"publisher","first-page":"557","DOI":"10.21037\/jtd.2018.01.71","volume":"10","author":"LK Er","year":"2018","unstructured":"Er, L. K., Wu, V.-C. & TAIPAI Study Group. Call for screening for primary aldosteronism: an underdiagnosed and treatable disease. J. Thorac. Dis. 10, 557\u2013559 (2018).","journal-title":"J. Thorac. Dis."},{"key":"714_CR316","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/S2213-8587(18)30071-8","volume":"6","author":"B Williams","year":"2018","unstructured":"Williams, B. et al. Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. Lancet Diabetes Endocrinol. 6, 464\u2013475 (2018).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"714_CR317","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1161\/HYPERTENSIONAHA.124.22753","volume":"81","author":"JB de Freminville","year":"2024","unstructured":"de Freminville, J. B. et al. Prevalence and risk factors for secondary hypertension in young adults. Hypertension 81, 2340\u20132349 (2024).","journal-title":"Hypertension"},{"key":"714_CR318","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1111\/jch.14173","volume":"23","author":"RM Alnazer","year":"2021","unstructured":"Alnazer, R. M., Veldhuizen, G. P., Kroon, A. A. & de Leeuw, P. W. The effect of medication on the aldosterone-to-renin ratio. A critical review of the literature. J. Clin. Hypertens. 23, 208\u2013214 (2021).","journal-title":"J. Clin. Hypertens."},{"key":"714_CR319","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.ancard.2015.04.017","volume":"64","author":"M Barigou","year":"2015","unstructured":"Barigou, M. et al. Effect of postural changes on aldosterone to plasma renin ratio in patients with suspected secondary hypertension. Ann. Cardiol. Angeiol. 64, 169\u2013174 (2015).","journal-title":"Ann. Cardiol. Angeiol."},{"key":"714_CR320","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1210\/jc.2010-2918","volume":"96","author":"AH Ahmed","year":"2011","unstructured":"Ahmed, A. H. et al. Effect of contraceptives on aldosterone\/renin ratio may vary according to the components of contraceptive, renin assay method, and possibly route of administration. J. Clin. Endocrinol. Metab. 96, 1797\u20131804 (2011).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"714_CR321","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1210\/jc.2010-2603","volume":"96","author":"AH Ahmed","year":"2011","unstructured":"Ahmed, A. H. et al. Effects of two selective serotonin reuptake inhibitor antidepressants, sertraline and escitalopram, on aldosterone\/renin ratio in normotensive depressed male patients. J. Clin. Endocrinol. Metab. 96, 1039\u20131045 (2011).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"714_CR322","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1161\/HYPERTENSIONAHA.109.134825","volume":"54","author":"JD Snoep","year":"2009","unstructured":"Snoep, J. D. et al. Time-dependent effects of low-dose aspirin on plasma renin activity, aldosterone, cortisol, and catecholamines. Hypertension 54, 1136\u20131142 (2009).","journal-title":"Hypertension"},{"key":"714_CR323","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1373\/clinchem.2016.255737","volume":"62","author":"L Lam","year":"2016","unstructured":"Lam, L., Chiu, W. W. & Davidson, J. S. Overestimation of aldosterone by immunoassay in renal impairment. Clin. Chem. 62, 890\u2013891 (2016).","journal-title":"Clin. Chem."},{"key":"714_CR324","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1515\/cclm-2022-1190","volume":"61","author":"P Bonnitcha","year":"2023","unstructured":"Bonnitcha, P., Rigdwell, M., Ward, P. & Chesher, D. Standard \u221220 \u00b0C freezer storage protocols may cause substantial plasma renin cryoactivation. Clin. Chem. Lab. Med. 61, 1428\u20131435 (2023).","journal-title":"Clin. Chem. Lab. Med."},{"key":"714_CR325","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1210\/clinem\/dgab348","volume":"106","author":"A Hung","year":"2021","unstructured":"Hung, A. et al. Performance of the aldosterone to renin ratio as a screening test for primary aldosteronism. J. Clin. Endocrinol. Metab. 106, 2423\u20132435 (2021).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"714_CR326","doi-asserted-by":"publisher","DOI":"10.1093\/ejendo\/lvac002","volume":"188","author":"M Naruse","year":"2023","unstructured":"Naruse, M. et al. International multicenter survey on screening and confirmatory testing in primary aldosteronism. Eur. J. Endocrinol. 188, lvac002 (2023).","journal-title":"Eur. J. Endocrinol."},{"key":"714_CR327","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.mce.2013.11.022","volume":"383","author":"CE Gomez-Sanchez","year":"2014","unstructured":"Gomez-Sanchez, C. E. et al. Development of monoclonal antibodies against human CYP11B1 and CYP11B2. Mol. Cell Endocrinol. 383, 111\u2013117 (2014). The development and wide distribution of selective antibodies to the steroidogenic enzymes allowed the immunohistochemical evaluation of adrenal lesions responsible for aldosterone (CYP11B2) or cortisol (CYP11B1) production in lesions of the adrenal cortex and profoundly modified our comprehension of PA pathophysiology.","journal-title":"Mol. Cell Endocrinol."}],"container-title":["Nature Reviews Disease Primers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41572-026-00714-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41572-026-00714-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41572-026-00714-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T07:02:15Z","timestamp":1782370935000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41572-026-00714-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":327,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["714"],"URL":"https:\/\/doi.org\/10.1038\/s41572-026-00714-w","relation":{},"ISSN":["2056-676X"],"issn-type":[{"value":"2056-676X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,25]]},"assertion":[{"value":"14 May 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.V. reports research funding from the National Institutes of Health, Doris Duke Charitable Foundation and Ventus Charitable Foundation. He also reports consulting fees from Mineralys, AstraZeneca, Corcept, HRA Pharma, Vertex and Moderna. G.A.K. serves as an unpaid scientific adviser to the Primary Aldosteronism Foundation and received a travel grant for the Endocrine Society 2025 guideline panel. P.M. reports educational speaker fees from Diasorin, Roche, AstraZeneca and Boehringer. A.F.T. served as an adviser for AstraZeneca. J.Y. served as an advisor and speaker for AstraZeneca, with fees paid to the research institute. A.L. received research grants as an investigator in studies from Recordati Canada Rare Diseases and Pfizer Canada, serves on advisory boards and is a speaker for Recordati Canada Rare Diseases; he receives royalties as editor of the adrenal section of UpToDate and Encyclopedia of Endocrine Diseases, and is co-inventor on a patent for endocrine diseases related to KDM1A at the Universit\u00e9 Paris-Saclay.\u00a0T.A.W., V.-C.W. and M.-C.Z. declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"39"}}